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ABSTRACT 
Cardiovascular disease (CVD) has historically been increased in type 1 diabetes compared to the 
general population, but no contemporary estimates of risk are available in the United States.  
Additionally, the reasons for this increased risk are not fully understood, as the hyperglycemia 
that characterizes type 1 diabetes is itself an inconsistent predictor of CVD incidence. Thus, the 
objective of this dissertation is to quantify the contemporary incidence and excess risk of CVD in 
young adults <45 years old with type 1 diabetes and to utilize novel statistical methods to 
address limitations in the analyses of longitudinal cohort studies, in an effort to better understand 
the risk factor patterns that lead to CVD in this population.  
Data are from the Pittsburgh Epidemiology of Diabetes Complications study, a 
prospective cohort study of childhood-onset type 1 diabetes diagnosed at Children’s Hospital of 
Pittsburgh between 1950 and 1980.  CVD data from the background Allegheny County, 
Pennsylvania population were used to calculate age- and sex-matched standardized mortality 
(SMR) and incidence rate ratios (IRR).  Using tree-structured survival analysis (TSSA), formal 
subgroup analysis was performed to identify groups at varying levels of risk for CVD, based on 
threshold effects of continuous risk factors. Joint models were used to simultaneously model the 
longitudinal trajectory of HbA1c and time to CVD incidence.  
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CARDIOVASCULAR DISEASE IN TYPE 1 DIABETES:   
QUANTIFYING RISK AND ADDRESSING LIMITATIONS  
IN THE ANALYSIS OF LONGITUDINAL COHORT STUDIES 
 Rachel G. Miller, PhD 
University of Pittsburgh, 2016
v 
CVD risk was shown remain significantly increased in this type 1 diabetes cohort. TSSA 
identified a range of risk groups, which were defined by combinations of diabetes duration, non-
HDL cholesterol, albumin excretion rate, and white blood cell count. The longitudinal trajectory 
of HbA1c was associated with CVD risk, similarly across all manifestations of CVD, including 
coronary artery disease, stroke, and lower extremity arterial disease, which is a new finding in 
this cohort.  This work has important impacts on public health, as it confirms that individuals 
with type 1 diabetes continue to be at increased risk for CVD and demonstrates that novel 
statistical methods should be utilized as a complement to traditional methods to increase 
understanding of disease etiology. 
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1.0  INTRODUCTION 
1.1 TYPE 1 DIABETES 
1.1.1 Introduction and Epidemiology 
Type 1 diabetes is an autoimmune disease in which the insulin-secreting beta cells in the 
pancreas are destroyed, so that the body is unable to produce insulin, a hormone that is required 
to convert sugar into energy.  The pathogenesis of type 1 diabetes is complex and not well 
understood, with both genetic and environmental factors likely interacting to trigger the 
autoimmune response that targets the pancreatic beta cells.  The clinical presentation of type 1 
diabetes includes weight loss, frequent urination, extreme thirst, and fatigue (1).  In the United 
States, it is estimated that between 740,000 and 970,000 individuals have type 1 diabetes (2) and 
the incidence has been increasing significantly in recent decades (3–6) by greater than 3% per 
year (5,7) with a corresponding increase in prevalence of 23% between 2001-2009 reported by 
the SEARCH for Diabetes in Youth Study (8).   Type 1 diabetes most often manifests in 
childhood or adolescence, reflecting the initiation of islet autoimmunity early in life (9). In high 
incidence countries, males are at a greater risk of developing type 1 diabetes than females, and 
this difference does not seem to be explained by sex differences in environmental exposures, 
while in lower incidence countries this sex difference is attenuated (10).  There are also 
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geographic differences in type 1 diabetes rates, with the highest rates in Finland and Sardinia (7) 
and the lowest rates in Asia (11).  Generally, incidence is higher in the northern hemisphere 
compared to the southern (11).    
1.1.2 Pathophysiology and Risk Factors 
The pathophysiology of type 1 diabetes is dominated by an autoimmune response of 
CD4+ T-lymphocytes against the pancreatic beta cells, however the underlying cause for this 
process is not known.  Various prospective cohort studies have shown that the clinical 
presentation of type 1 diabetes is preceded by the presence of islet autoantibodies (9,12–14).  
Additionally, as the progression from autoimmunity to clinical diabetes has been shown to 
proceed in a linear fashion, the age when these autoantibodies are first detected seems to relate to 
an increased risk of progression to type 1 diabetes (15) and determine the age of type 1 diabetes 
onset (16).  The Finnish DIPP study reported a median of 2.5 years from autoantibody 
seroconversion until the onset of type 1 diabetes (17), and a similar rate of progression has also 
been observed in other cohorts (18).  Islet autoantibodies have been found to be present in over 
90% of individuals at type 1 diabetes diagnosis and though these autoantibodies do not directly 
cause type 1 diabetes, they can be used clinically to distinguish type 1 and type 2 diabetes (19).  
While the cause of beta cell autoimmunity is not fully understood, there is evidence for 
contributions from genetic and environmental factors, including dietary, lifestyle, and infectious 
factors.  The most well established genetic factor is the human leukocyte antigen (HLA) locus, 
located on chromosome 6p21.  Individuals with the HLA-DR3-DQ2/DR4-DQ8 genotype are at 
the highest risk for developing type 1 diabetes, with an approximate 20-fold increased risk 
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compared to the general population (20).  The risk in these individuals is even higher if they also 
have first-degree relatives with type 1 diabetes (21).  Additionally, other HLA genes confer 
intermediate risk (22) and more recently the protein tyrosine phosphatase nonreceptor type 22 
(PTPN22) has also been shown to be a strong predictor of type 1 diabetes (23–26), as well as 
other autoimmune diseases (25). 
The evidence for potential environmental contributors to type 1 diabetes include 
outbreaks (27) and the increasing incidence of type 1 diabetes among the lower-risk HLA 
genotypes that has been observed in recent years (28–30).  Dietary factors have been explored 
and in both the DAISY (31) and BABYDIAB (32) cohorts, the introduction of cereals before 3 
months of age was associated with an increased risk of islet autoimmunity, particularly in the 
high risk HLA genotype.  Early exposure to cow’s milk has also been implicated as a predictor 
of islet autoimmunity (33–36) and the Ig-G antibodies that bind bovine insulin show cross-
reactivity with human insulin (33,37,38). Insulin resistance and increasing rates of childhood 
obesity have also been hypothesized to be risk factors for type 1 diabetes and underlie the 
“accelerator hypothesis” (39).   In support of this hypothesis, studies have found that insulin 
resistance is associated an increased risk of progression to type 1 diabetes in individuals with 
islet autoimmunity (40–44).  Finally, enteroviruses have been proposed as another potential 
trigger of islet autoimmunity (45–47) and their effect may interact with other environmental 
factors, such as diet, to increase the risk of progression to type 1 diabetes (16,48). 
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1.2 MORTALITY TRENDS IN TYPE 1 DIABETES 
Type 1 diabetes (T1DM) is consistently associated with increased mortality, though the 
excess risk seems to have decreased over recent years (49). Large differences in T1DM mortality 
are seen across countries, with smaller excess mortality generally observed in European 
countries and larger excess observed in the United States (49). There is also a sex difference, 
with women with T1DM having a greater excess mortality compared to men (50). More recent 
reports from the Scottish Registry Linkage Study and the Swedish National Diabetes Register 
both show that T1DM continues to be associated with an increased mortality compared to the 
general population across all age groups, with younger women at particularly high risk (51,52).  
A recent report from Australia further suggests that younger patients (<40 years) with T1DM are 
not experiencing a decline in “diabetes” mortality, in contrast to other causes and age groups 
(53).  Contemporary data from the United States focused on young adults with long-duration 
T1DM are lacking, though recent findings from the Diabetes Control and Complications 
Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study show 
lower all-cause mortality with intensive insulin therapy compared to conventional therapy (54). 
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1.3 CARDIOVASCULAR DISEASE IN TYPE 1 DIABETES 
1.3.1 Introduction and Epidemiology 
Cardiovascular disease (CVD), including coronary artery disease (CAD), cerebrovascular 
disease, and peripheral vascular disease, is a major complication of type 1 diabetes.  As in the 
general population, CVD is a major contributor to morbidity and mortality in individuals with 
type 1 diabetes, however the risk of CVD is greatly increased in type 1 diabetes (55).  The 
reasons for this increased risk are not fully understood, as the hyperglycemia that characterizes 
type 1 diabetes is itself an inconsistent predictor of CVD incidence (56–64). The cumulative 
incidence for CAD by age 55 years has been estimated to be as high as 35% in type 1 diabetes, 
compared to <10% in the nondiabetic population (55).  The risk of stroke is also elevated in type 
1 diabetes and has been estimated to be approximately four times higher in type 1 diabetes 
compared to the nondiabetic population (65,66).  Likewise, the risk of peripheral vascular 
disease (PVD) is also higher in diabetes, with the incidence estimated to be approximately 5 
times greater in individuals with diabetes compared to those without in the Framingham Study 
(67). Notably, the gender difference in CVD incidence seen in the general population seems to 
be narrowed in diabetes, so that women have nearly the same risk as men (56,68). 
During the 1980s, CVD risk was much greater in T1DM compared to the general 
population in two United States cohorts (55,69), including CVD mortality (70,71), though data 
from the DCCT/EDIC study has shown a reduction in CVD incidence with intensive insulin 
therapy (72). The Scottish Registry Linkage Study concludes that while the relative risk for CVD 
mortality associated with T1DM has declined, there remains a significantly elevated risk 
compared to the general population (51). The new American College of Cardiology/American 
6 
Heart Association (ACC/AHA) cholesterol guidelines have proposed a ten-year CVD risk 
threshold of ≥7.5% for statin therapy for those aged 40-75 years with an LDL-c >70 mg/dl (73), 
but there are no clear guidelines for patients with long duration childhood-onset T1DM aged <40 
years.  There are also no recent reports from the United States quantifying contemporary CVD 
risk in T1DM. 
1.3.2 Risk Factors 
As stated above, glycemia has not consistently been associated with CVD incidence in 
type 1 diabetes.  In the DCCT/EDIC study, however, the intensive diabetes therapy arm had 
significantly lower incidence of CAD compared to the conventional therapy arm (74).  In 
contrast, in observational studies, HbA1c has not been a consistent predictor of CVD events 
(58,60,61,66,75–77).  One potential explanation for these seemingly discordant results is that, in 
the DCCT, intensive therapy was begun early in the course of diabetes, raising the suggestion 
that glycemia may play a role in the initiation of atherogenesis (78).  Despite the level of HbA1c 
not predicting CAD incidence, in the EDC study, decreasing HbA1c over time has been 
associated with a lower risk of CAD (62), as shown in Figure 1. 
7 
Figure 1. Coronary Artery Disease (CAD) incidence by HbA1c change category in the EDC study. 
Fallers: a fall of 1 standard deviation or greater; Risers: a rise of 1 standard deviation or 
greater, Stable: change within 1 standard deviation.  Adapted from Prince et al. 
Diabetologia. 2007; 50(11): 2280-8.  
Additionally, HbA1c variability, but not mean HbA1c over time, was predictive of CVD 
events in the FinnDiane study (77).  In contrast to this inconsistent relationship between HbA1c 
and CAD, glycemia has been more consistently associated with an increased risk of PAD 
(58,79,80).  This difference may indicate that hyperglycemia is more strongly associated with 
stable atherosclerosis, which characterizes PAD, rather than plaque rupture, which characterizes 
the acute coronary events (78).  In the general population, the majority of acute coronary events 
are precipitated by plaque rupture and a small proportion is due to plaque erosion (81,82).  In 
type 1 diabetes, these proportions are reversed with the majority of events due to plaque erosion 
(81,82), adding more evidence that hyperglycemia is associated with stable atherosclerosis. 
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 Other diabetes complications, specifically nephropathy and neuropathy are strong 
predictors of CVD incidence.  While nephropathy is considered a major risk factor for CVD in 
type 1 diabetes (83–86), this relationship is not well understood.  In some cases, adjusting for the 
traditional cardiovascular risk factors that are potential confounders of the renal-CAD link does 
attenuate the relationship (60).  Also, in the EDC study, nephropathy seems to affect the 
presentation of CAD, such that individuals with ON are more likely to present with a “harder” or 
more severe event, like a myocardial infarction (63).  Additionally, nephropathy was found to be 
a stronger risk factor for CAD in men than in women (56), while in the Eurodiab study 
nephropathy predicted CAD incidence in both sexes (61).  Nephropathy is also a strong predictor 
of stroke (66).  Neuropathy has also been associated with an increased risk of CAD (75,87–91), 
but the nature of this association is not well understood.   
 In addition to the diabetes-specific factors already discussed, standard CVD risk factors 
are important predictors of CVD incidence in type 1 diabetes.  CVD risk factors appear at 
younger ages in type 1 diabetes (92).  Generally, lipid levels are not particularly high in type 1 
diabetes, but it has been reported by the SEARCH study investigators that in youth with type 1 
diabetes and poor glycemic control, lipids are often elevated (93).  The major standard risk 
factors also predict CVD incidence in type 1 diabetes, including blood pressure, lipids, and 
waist-hip ratio (56,75,94,95).  Inflammatory factors are also associated with CVD (96–98) and 
have recently been linked to the progression of coronary artery calcification in type 1 diabetes 
(99).  In general, type 1 diabetes is characterized by high levels of inflammatory cytokines (100–
103), which may contribute to the elevated risk of CVD in type 1 diabetes.  Although the risk of 
developing CVD is approximately equivalent by gender in type 1 diabetes, there is evidence that 
the risk factors for CVD differ in men and women (56).  Besides the aforementioned sex 
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difference in the relationship between CAD and nephropathy, smoking is a stronger risk factor in 
men, perhaps due to the fact that men are more likely to smoke or smoke more than women, 
while depressive symptomatology and physical activity appear to predict CAD more strongly in 
women (56). 
There also seems to be some variation in the relationship between specific risk factors 
and each manifestation of CVD, though few studies of type 1 diabetes have performed the direct 
comparisons needed to fully address this issue.  In a comparison of risk factors for CAD versus 
LEAD in the Pittsburgh EDC study, after 6 years of follow-up, hypertension, depressive 
symptomatology, and nephropathy were independently predictive of CAD only, while HbA1c 
and smoking were independently predictive of LEAD only (58).  Diabetes duration and serum 
lipids (HDL-cholesterol for CAD and LDL-cholesterol for LEAD) were predictive of both 
manifestations of CVD.  A report from the Wisconsin Epidemiologic Study of Diabetic 
Retinopathy comparing risk factors for CAD and stroke showed that smoking was an 
independent predictor of CAD only, while HbA1c was predictive of stroke only (75).   
 Genetic markers have also been identified as potentially important risk 
factors.  The haptoglobin gene seems to be strongly associated with CAD events (104) and 
coronary artery calcification (105) in type 1 diabetes, consistent with the relationship that had 
previously been reported in type 2 diabetes (106–108). The endothelial nitric oxide synthase 
(NOS3) gene and the receptor for advanced glycation end-products (RAGE) gene have also been 
linked to CVD in type 1 diabetes (109,110).    
Many questions remain regarding the prediction of CVD in type 1 diabetes.  One 
important issue is the need to develop a better understanding of the role of glycemia in the 
pathophysiology of CVD.  As discussed above, findings on the association between glycemia 
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and CVD have been mixed.  Another problem that remains is lack of type 1 diabetes-specific 
target levels for risk factors, as no trials have been undertaken in type 1 diabetes 
populations.  For example, the results of recent trials in type 2 diabetes show that intensive blood 
pressure control does not seem to decrease the risk of mortality or CVD (111–113), but it is 
unclear if this relationship is the same in type 1 diabetes, where individuals have longer disease 
duration at younger ages due to the earlier onset of type 1 diabetes.  Finally, more research needs 
to be done to determine if there are additional high risk subgroups of patients within type 1 
diabetes. 
1.4 LIMITATIONS OF COMMONLY USED STATISTICAL METHODS IN 
LONGITUDINAL COHORT STUDIES  
Typically, in longitudinal cohort studies, the association between risk factors and the 
occurrence of the outcome of interest is assessed using Cox proportional hazards regression.  The 
dependent variable in Cox regression is the hazard function of the outcome of interest, while the 
independent variable(s) are generally entered into the model in their continuous form to obtain a 
hazard ratio, an estimate of the relative risk (114).  When modeled in this manner, the association 
between risk factor and log cumulative hazard is assumed to be linear (114).  Thus, the 
possibility of a nonlinear relationship or a threshold which stratifies a risk factor into important 
subgroups is not considered.  It is also difficult to model and interpret higher order interactions 
using traditional regression methods.  Additionally, using these types of analyses, the full 
potential of the longitudinal trajectory of the risk factor data is not often utilized.  Instead, only 
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either baseline variables or the average values of risk factors are often used as predictors.  We 
will expand on these limitations in sections 1.4.1-1.4.3. 
1.4.1 Limitation 1:  Inadequate assessment of subgroups and higher order interactions 
Formal identification of important subgroups is not often attempted in observational 
cohort studies.  Even if identification of such subgroups is attempted, interactions between 
various groups are not assessed because it is very cumbersome to do so with traditional modeling 
techniques.  Studies where these types of analyses have been undertaken demonstrate the 
potential importance of such an approach.  For example, decision tree analyses of the Western 
Collaborative Group Study data identified various groups of men, based on interactions between 
obesity, age, and hypertension status, who were at very high risk of coronary heart disease 
mortality (115).  In the EDC study, these methods were used to identify subgroups of 
participants based on biologic risk factors who were at low risk for complications (116).  Genetic 
markers were then examined within the low risk groups and, using this approach, associations 
between the genes and complications emerged that were not observed in the overall study 
population (116). 
1.4.2 Limitation 2: Failure to assess nonlinearity 
As stated above, the commonly used regression techniques and tests for trend assume an 
underlying linear relationship between the exposure and the outcome.  If the true relationship is 
nonlinear, then inferences will be invalid, potentially leading to important clinical consequences 
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(117–119).  An example of this can been seen in the relationship between blood pressure and 
CVD (120).  Blood pressure has been shown to have a J-shaped relationship with CVD. 
However, in most studies only a linear relationship is examined.  Hence, there is the potential for 
misinformed clinical decisions to be made, if the increased risk at lower blood pressure is not 
recognized.  Determining an accurate representation of the shape of the relationship is critical for 
prevention efforts (121).  In cases where the relationship between a risk factor and outcome is U-
shaped, testing for a linear association may not detect a relationship at all (117,122).  Another 
drawback of assuming an underlying linear relationship is that the potential for threshold effects 
is not assessed. 
A common way to assess nonlinearity is to categorize or dichotomize the risk 
factor.  While this is a straightforward way to examine the shape of the association, it is usually 
based on arbitrary or sample-based groupings, which may not adequately describe the 
association or identify the optimal cut-points (123).  In many cases, different choices of 
groupings may also lead to differing conclusions (124–126).  Categorization also leads to less 
statistical efficiency, compared to using continuous variables (127) and results in a step-function, 
which is not biologically plausible (125). 
1.4.3 Limitation 3: Neglecting the full potential of longitudinal data 
Analyses of data from longitudinal cohort studies also rarely make full use of the 
information contained in the serially measured risk factors.  Commonly, baseline variables are 
used as predictors, but this approach, while generally providing valid results, does not account 
for changes in the variables over time that may affect risk (128).  For example, this approach 
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may underestimate the effect of risk factors that become important closer to the time of the 
event.  Stability and change of predictors is relevant for determining the likelihood of an 
individual having an event, thus incorporating within-subject patterns is important for obtaining 
a more complete understanding of the relationship between risk factor and outcome (128–131).  
In some cases, failing to utilize all available data may lead to invalid results (128). 
One common approach for accommodating change of risk factors in statistical analyses is 
to model change (132).  However, this approach does not account for the actual pattern of change 
and assumes a constant, linear increase or decrease over the follow-up and may also 
underestimate the variance of the factor (133).  Another common approach for utilizing 
longitudinal data is to model the average (or updated mean) risk factor over the follow-up, 
however this has similar drawbacks to modeling change, leading to a loss of important 
information (134). 
1.5 STATISTICAL APPROACHES TO ADDRESS LIMITATIONS OF 
TRADITIONAL METHODS  
In an attempt to overcome the aforementioned issues, the objective of this dissertation is 
to utilize statistical methods which can explore higher order interactions and important 
subgroups, accommodate potential nonlinearity, and make use of serially measured risk factors 
to better understand the association between the 20-year incidence of the various first 
manifestations of CVD and risk factors in the Pittsburgh Epidemiology of Diabetes 
Complications Study.  The details of these methods will be described in sections 1.5.1-1.5.3.  
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1.5.1 Identification of high risk subgroups and interactions using tree structured survival 
analysis 
The aims in using this approach are: 1) to determine whether there are meaningful 
subgroups at high risk for CAD, stroke, or PVD derived from the many variables measured in the 
EDC study and 2) to identify interactions between the groups.   These goals will be 
accomplished through the identification of particularly important categorical variables as well as 
identifying threshold effects or cut-points for continuous variables that divide the sample into 
high-risk subgroups.  Tree-structured survival analysis (TSSA), a decision tree approach that is 
able to take time to CVD event into account, will be used to accomplish this aim.  This approach 
will also facilitate the identification of important interactions between risk factors.  It is 
important to note that analyses using classification tree methods are exploratory in nature (135), 
however, they may be useful in identifying previously unknown high-risk subgroups and 
interactions between risk factors. 
TSSA falls under the general machine learning method of decision trees, which were 
initially proposed by Morgan and Sonquist in the 1960s (136) and refined by Quinlan in the 
1970s (137,138).  In 1984, Breiman et al. developed Classification and Regression Trees 
(CART), an algorithm which generated decision trees with continuous and categorical outcomes 
(139).  The general idea underlying decision tree construction is that attributes are split into 
subsets (nodes) and then these are again split by another attribute.  The process is repeated 
recursively until all instances within a node have the same outcome classification 
(140).   Traditionally, decision trees are used to derive subgroups for the prediction of a binary 
outcome.  However, in the 1980s and 90s, the decision tree framework was extended to 
accommodate time-to-event survival data with censored observations (141–143). Cross-
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validation is the most commonly used method for training and testing to find the best 
tree.  Rather than simply building a single tree and holding out a proportion of the data for 
testing, cross-validation is an iterative process which repeats the process several times on random 
samples from the data (140).  Then error rates from the various iterations are used to identify the 
best fitting and most parsimonious tree (144).   
To accomplish the proposed aims, the rpart (recursive partitioning) routine in the 
statistical package R version 3.0.2 (145) will be utilized.  The rpart routine has been described in 
detail by Therneau and Atkinson (144).  The routine uses the basic method of recursive 
partitioning described above.  Subgroup splits are chosen based on an “impurity function”, such 
as the information index and the Gini index, where the value that minimizes these functions is 
chosen as the best cut-point.  In order to model data where the outcome is a time to event with 
censored observations, the time values are scaled so that log(survival) is linear under an 
exponential model, which results in a tree that is equivalent to the local full likelihood decision 
tree for relative risks (143).  To avoid over-fitting, the resulting tree is pruned by selecting a tree 
size with the minimum cross-validated error, as measured by a complexity parameter 
(144).  Importantly, rpart is able to accommodate missing data and as long as each subject has 
data for at least one independent variable, they are included.  
TSSA has previously been utilized to analyze 10-year follow-up data from the EDC study 
(116).  In those analyses, separate decision trees were constructed to identify the subgroup at the 
lowest risk of coronary artery disease, confirmed distal symmetric polyneuropathy, and overt 
nephropathy, based on biologic risk factors only.  Within the lowest risk groups, the relationship 
between genetic markers and the outcome were examined.  The current proposed TSSA analyses 
differ from the prior analyses in the following ways: 1) the follow-up period now reaches 24 
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years, so there are now 192 cases of CAD, compared to only 99 in the original analysis, and 2) 
the objective of the current analysis is to identify subgroups at particular risk for both total CVD 
and the different first manifestations of CVD (CAD, stroke, and PAD).  Data from EDC 
participants who were free of CVD at baseline will be utilized to construct a decision tree with 
time to CVD event as the outcome with the rpart routine in R.  Separate trees will also be 
constructed for each of the three first manifestations of CVD, in an attempt to identify subgroups 
and potentially important interactions between risk factors which lead to particularly high or low 
risk for developing each specific manifestation. 
Decision trees have many advantages in epidemiologic research, most notably that the 
results are presented in a manner that is similar to the thinking process used to approach medical 
questions.  Thus, the resulting trees are well-suited for clinical application (135,146).  Another 
important advantage is that trees provide a clear representation of interactions between attribute 
subgroups.  Demonstration of higher-order interactions using statistical models is complicated 
and cumbersome, but they can be intuitively presented using decision trees 
(115,135,146).  Decision trees also have the advantage of avoiding various statistical 
assumptions, such as linearity or proportional hazards (146).  As mentioned above, the major 
limitation of decision trees is that the method is considered to be exploratory and does not assess 
the relative importance of risk factors (135).  Therefore, the resulting subgroups and interactions 
may not be definitive and should be replicated in other populations.  Finally, it is important to 
consider the biologic and clinical plausibility of the results, and to perform sensitivity analyses to 
avoid misleading inferences (135,147).  
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1.5.2 Assessment of nonlinear associations between risk factors and incidence of CVD 
outcomes using restricted cubic splines 
The aim of using this approach is to establish the shape of the relationship between risk 
factors and risk of CVD using restricted cubic splines.  Allowing for potential nonlinear 
associations between risk factors and CVD incidence may lead to the detection of threshold 
effects or protective effects at certain levels of a factor (i.e. U- or J-shaped relationships, as 
described above).  Utilizing splines to assess nonlinear relationships helps to avoid pitfalls of 
categorization or dichotomization, such as loss of power and bias due to choice of cut-points 
(117,124,126) and also allow the general shape of the relationship to be inferred (117).  These 
issues are detailed in the 2005 paper by May and Bigelow, in which various methods of 
assessing nonlinear, dose response relationships were compared (117).  They concluded that, for 
detection of a nonlinear, dose-response relationship, restricted splines were best at representing 
the shape of the association, compared to linear, categorization, and fractional polynomial 
approaches (117).  Spline regression is very flexible and can represent almost any possible shape 
of an association (119).  While underutilized in epidemiologic studies, spline regression has 
revealed interesting nonlinear relationships between risk factors and CVD outcomes.  In a recent 
report from the Tehran Lipid and Glucose study, fasting plasma glucose was found to have a 
curvilinear relationship with CVD events and both all-cause and CVD mortality (148).  Blood 
pressure has been shown to have a J- or U-shaped relationship with CVD events in many studies 
(149–154).  Examples where this issue was formally examined using spline regression include 
the Cardiovascular Health Study (155), where the relationship was determined to be linear, and 
the Treating to New Targets (TNT) trial (120), where the relationship was J-shaped. 
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Briefly, spline regression is characterized by piecewise functions where each piece is a 
low-order polynomial defined over a certain interval of the continuous variable (126).  The point 
between any two intervals is called a “knot”, denoted k.  Usually, continuity constraints of the 
curve itself and perhaps the corresponding first or second derivatives are imposed at the knots 
that connect the piecewise polynomials giving the spline a smooth appearance.  Generally, five 
knots are used (or fewer for smaller data sets) and these are located at fixed percentiles 
(119).  Placing the knots at fixed percentiles helps to avoid subjective bias and makes results 
comparable across variables and studies (156).  Commonly, for k=5, knots are placed at the 5th, 
25th, 50th, 75th, and 95th percentiles (156).  Spline functions tend to be quite flexible and knot 
placement does not significantly affect results (157).   An important characteristic of spline 
functions is that the slope of each interval is constrained to be the same as the slope of the next 
interval at their common knot to avoid a sudden change in risk between intervals (i.e. smoothed) 
(126,158).  Cubic spline functions, which are sums of third degree polynomials, are commonly 
chosen and produce very smooth curves (126).  “Restricted” spline functions are constrained to 
be linear before the first and after the last knot.  This restriction helps to avoid poor model fit that 
often occurs at extreme ends of the distributions (117,126,158). 
Restricted cubic splines are created by 1) dividing the continuous variable into intervals 
using knots at fixed percentiles, 2) create a new variable for each knot that is zero below the knot 
and a third order polynomial above, 3) smooth the slopes of the piecewise functions at the knots, 
as described above, and 4) restrict the first and last intervals to be linear (119).   To determine 
statistical significance, first, the null hypothesis that the slopes of all of the piecewise functions 
are equal to zero is tested.  If this initial test is not statistically significant, then the factor and 
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outcome are not associated, but if the initial test is significant, then a second test is performed 
with the null hypothesis that the nonlinear coefficients are zero.  
The restricted cubic spline method will be utilized with the EDC data to determine 
whether risk factors are related to CVD incidence in a nonlinear fashion and whether the shape 
of the relationships differs by the first manifestation of CVD.  No systematic assessment of 
nonlinear relationships between risk factors and CVD incidence has been previously undertaken 
using EDC data. Prevalent cases of CVD will be excluded and risk factor variables will be 
modeled using restricted cubic splines in Cox proportional hazards models for risk of incident 
CVD.  All analyses will be performed using the RCS macro for Cox regression with restricted 
cubic splines (156) in SAS 9.3 (SAS Institute Cary, NC).   The RCS macro also provides a 
graphical representation of the estimated spline function, which facilitates interpretation of the 
results (156). 
The major advantage of using restricted cubic splines is that the shape of the relationship 
between risk factors and outcomes can be inferred (117).  Failing to consider possible 
nonlinearity could lead to false null results or misrepresentation of the true relationship as being 
linear when it is not (117).  Splines also provide more power to detect a relationship compared to 
other methods of assessing nonlinearity, such as categorization (159).   The main limitation of 
cubic splines is that they can be sensitive to the choice of knot location (126), so it is important 
to test different locations and perform sensitivity analyses. 
The results of these analyses examining the dose-response relationship between risk 
factors and cardiovascular disease in the EDC cohort are presented in Appendix A. 
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1.5.3 Utilizing the serial measured risk factor data in the EDC study to predict the 
incidence of cardiovascular disease using joint modeling of longitudinal and time-to-event 
data 
The aim of this approach is to assess the predictive capability of serially measured risk 
factor data on the incidence of total cardiovascular disease, as well as its various manifestations, 
using joint longitudinal and time-to-event models.  Utilizing the longitudinal data available in the 
EDC study in this manner will accommodate information on both the rate of change of 
covariates, as well as their relationship with the time to CVD events.  Joint modeling is not 
commonly used in epidemiologic studies, though the method has been applied in varied 
settings.  The HIV literature has several examples of joint modeling being used to determine 
whether longitudinal CD4+ counts improve the prediction of survival (128,160–162).  Additional 
recent examples of joint modeling in epidemiologic studies include analyses to determine 
whether longitudinal measures of allograft valve function were predictive of patient survival 
(163) and to examine the relationship between longitudinal measures of red blood cell 
distribution width and survival in heart failure patients (164). 
 Joint modeling allows both the longitudinal repeated covariates, usually modeled using 
random effects, and the time-to-event data to be modeled together.   Briefly, a joint model 
consists of two sub-models.  A mixed-effects model defines the change over time of the 
longitudinal covariate.  The modeled random effects are simultaneously included in a survival 
model, so that the relationship between the pattern of change of covariates and time to the event 
of interest can be estimated (131).  These random effects, or subject-specific deviations from the 
average effect, are assumed to be the underlying link between the longitudinal repeated measures 
and the subject-specific hazard for the time-to-event outcome (128). 
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 Joint modeling can be performed using the joineR routine in R.  Before starting, the 
data must be stored in three “data frames”: 1) the repeated measures data must be stored in a 
frame with the format of one row per observation per subject (i.e. multiple rows per subject), 
with a column for id and another for the corresponding follow-up time, 2) the time-to-event 
survival data must be stored in a frame with one row per subject, and 3) the baseline covariate 
data for adjustment must also be stored in a frame with one row per subject (165).  Beginning 
with exploratory analyses, the individual profiles of repeated measures data can be plotted using 
joineR for subgroups of the subjects, to examine any potential important patterns or outlying 
subjects.  Then longitudinal and time-to-event hazard sub-models can be fit, specifying a random 
intercept and slope, which corresponds to the previously described method detailed by Wulfsohn 
and Tsiatis (160,165). 
 Joint modeling will be utilized with the EDC data to determine whether 
longitudinal patterns of covariate change predict CVD incidence and whether these relationships 
differ by the first manifestation of CVD.  While survival analyses and mixed models analyses 
have been performed extensively on EDC data, jointly modeling both processes has not 
previously been carried out.  The 24-year follow-up data for CVD incidence will be used in the 
current analyses.  Clinical risk factors were measured every two years from baseline (1986-1988) 
until the 10-year follow-up (1996-1998) and then again at 18-years.  Prevalent cases of CVD will 
be excluded and repeatedly measured risk factor variables will be modeled as predictors in joint 
models where the outcome is time to first CVD event.  Models will be repeated separately with 
time to CAD, stroke, and PVD as the outcome.  All analyses will be performed using the joineR 
routine in R (145,165). 
22 
 The major advantage of joint modeling is that it allows the relationship between 
longitudinal repeated measures and a time-to-event outcome to be examined.  Using simpler 
methods, such as modeling the two processes separately, may lead to bias if some subjects 
survive far beyond the most recent follow-up.  Our proposed joint model is able to account for 
this differential follow-up time by including the subject-specific random effects within the 
survival model (128,166).  As emphasized by Lim et al., joint modeling may be particularly 
useful when the goal is to use longitudinal measures of biomarkers to improve prediction of an 
event (128). The main limitation of joint modeling is the potential for bias if the censoring 
process is related to the longitudinal repeated measures data (i.e. informative censoring) 
(160).  Another limitation is that joint modeling is not included in any of the widely used 
commercial software packages, so model fitting is more difficult than when using more 
established methods.   
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2.0  ESTIMATING CONTEMPORARY TOTAL MORTALITY AND 
CARDIOVASCULAR DISEASE RISK IN YOUNG ADULTS WITH TYPE 1 DIABETES 
2.1 ABSTRACT 
The degree to which mortality and cardiovascular disease (CVD) incidence remains 
elevated in young US adults with type 1 diabetes (T1DM) is unclear. We determined 
contemporary rates for adults <45 years old with long-standing, childhood-onset T1DM. 
Members of the Epidemiology of Diabetes Complications (EDC) study cohort <45 years old 
during the 1996-2012 follow-up period (n=502) were studied. Mortality and CVD rates were 
calculated for ages 30-39 and 40-44 years. Data from the background Allegheny County, 
Pennsylvania population were used to calculate age- and sex-matched standardized mortality 
(SMR) and incidence rate ratios (IRR). In both age groups, the SMR for total mortality was 
approximately 5. CVD mortality SMRs ranged from 20-33. Hospitalized CVD IRR was 
approximately 8; revascularization procedures account for much of the increased risk. For all 
outcomes the relative risk was larger in women. Participants aged 30-39 years had 6.3% absolute 
10-year CVD risk, approaching the American College of Cardiology/American Heart
Association recommended cut-point of 7.5% for initiation of statin therapy in older adults. Total 
and CVD mortality and hospitalized CVD are all significantly increased in this contemporary US 
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cohort of young adults with long-standing T1DM. These findings support more aggressive risk 
factor management in T1DM, especially among women. 
2.2 INTRODUCTION 
Type 1 diabetes (T1DM) is consistently associated with increased mortality, though the 
excess risk seems to have decreased over recent years (49).  Large differences in T1DM 
mortality are seen across countries, with smaller excess mortality generally observed in 
European countries and larger excess observed in the United States (49). There is also a sex 
difference, with women with T1DM having a greater excess mortality compared to men (50). 
More recent reports from the Scottish Registry Linkage Study and the Swedish National 
Diabetes Register both show that T1DM continues to be associated with an increased mortality 
compared to the general population across all age groups, with younger women at particularly 
high risk (51,52).  A recent report from Australia further suggests that younger patients (<40 
years) with T1DM are not experiencing a decline in “diabetes” mortality, in contrast to other 
causes and age groups (53).  Contemporary data from the United States focused on young adults 
with long-duration T1DM are lacking, though recent findings from the Diabetes Control and 
Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) 
study show lower all-cause mortality with intensive insulin therapy compared to conventional 
therapy (54).   
Atherosclerotic cardiovascular disease (CVD), including coronary artery disease (CAD) 
is a major complication of T1DM (78). During the 1980s, CVD risk was much greater in T1DM 
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compared to the general population in two United States cohorts (55,69), including CVD 
mortality (70,71), though data from the DCCT/EDIC study has shown a reduction in CVD 
incidence with intensive insulin therapy (72). The Scottish Registry Linkage Study concludes 
that while the relative risk for CVD mortality associated with T1DM has declined, there remains 
a significantly elevated risk compared to the general population (51). The new American College 
of Cardiology/American Heart Association (ACC/AHA) cholesterol guidelines have proposed a 
ten-year CVD risk threshold of ≥7.5% for statin therapy for those aged 40-75 years with an 
LDL-c >70mg/dl (73), but there are no clear guidelines for patients with long duration 
childhood-onset T1DM aged <40 years.  
As there are no reports from the United States quantifying contemporary mortality and 
CVD risk in young adults with long duration T1DM, our objective was to determine such rates 
for individuals <45 years old with long-standing, childhood-onset T1DM for the years 1996-
2012 and to compare these data from the Pittsburgh EDC Study to the age-matched background 
population in Allegheny County, Pennsylvania. 
2.3 METHODS 
2.3.1 Study Design and Population 
The Pittsburgh EDC Study is a prospective cohort study of childhood-onset (<17 years 
old) T1DM. All participants were diagnosed, or seen within one year of diagnosis, at Children’s 
Hospital of Pittsburgh between 1950 and 1980. The cohort has been described in detail 
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elsewhere (167,168). In brief, participants have been followed since 1986-1988, initially with 
biennial examinations and questionnaires for ten years and thereafter with biennial 
questionnaires and further examinations at 18 and 25 years post-baseline. The current analyses 
were restricted to EDC participants who were <45 years old during the January 1, 1996 to 
December 31, 2012 follow-up period (n=502). Research protocols were approved by the 
University of Pittsburgh institutional review board and all participants provided written informed 
consent.   
2.3.2 Ascertainment of Mortality and Cardiovascular Outcomes 
In the EDC study, mortality was ascertained using medical records, death certificates, 
autopsy reports, and/or interview with next of kin and classified according to the Diabetes 
Epidemiology Research International (DERI) system (169) by a committee of physicians. CVD 
mortality was defined as fatal CAD, myocardial infarction, or stroke. Incidence of nonfatal CVD 
events (i.e. myocardial infarction, hospitalized coronary artery bypass graft, hospitalized 
angioplasty, and stroke) was self-reported by the study participant and confirmed by medical 
records. 
Mortality data for the age-matched background Allegheny County, Pennsylvania 
population between 1996-2012 were obtained through the Allegheny County Health Department 
and provided by the Division of Health Informatics, Pennsylvania Department of Health (the 
Department of Health specifically disclaims responsibility for any analyses, interpretations, or 
conclusions). The data were abstracted using the Pennsylvania Department of Health 
Epidemiologic Query and Mapping System (EpiQMS) by selecting total deaths, and separately, 
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coronary heart disease deaths (ICD10/ICD9: I11, I20-I25, I516/402, 410-414, 4292) and stroke 
deaths (ICD10/ICD9: I60-69/430-438). CVD hospitalization data for the age-matched 
background Allegheny County, Pennsylvania population were only available for the years 2004-
2010 and were abstracted from Pennsylvania Health Care Cost Containment Council (PAHC4) 
data and obtained through the Allegheny County Health Department. 
2.3.3 Risk Factor Assessment 
Fasting blood samples were taken to measure HbA1, lipids, and lipoproteins.  HbA1 
values were converted to DCCT-aligned values using a regression equation derived from 
duplicate assays (DCCT HbA1c=0.14 + 0.83[EDC HbA1]) (62). Serum total cholesterol and 
triglycerides were determined enzymatically (170,171) and HDL cholesterol was determined 
using a modified precipitation technique (172) based on the lipid research clinics method (173). 
LDL-cholesterol levels were calculated from the measurements of total cholesterol, triglycerides 
and HDL-cholesterol using the Friedwald equation (174).  Use of lipid-lowering therapy was 
self-reported. Blood pressure readings were taken according to the Hypertension Detection and 
Follow-Up protocol (175) and hypertension was defined as having either blood pressure >140/90 
or self-reported use of blood pressure lowering therapy. Urinary albumin was measured by 
immunonephelometry (176). Albumin excretion rate (AER) was calculated for each of three 
timed urine samples (24-hour, overnight, and 4-hour collections obtained over a two week 
period); the median of the three AERs was used in analyses. Current smoking status was 
obtained by self-report.   
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2.3.4 Statistical Analyses 
Analyses to quantify total mortality, CVD mortality, and CVD event rates included EDC 
data from the complete follow-up period between 1996 and 2012. Crude rates were calculated as 
the total number of events per 100,000 person years with 95% confidence intervals for the age 
groups 30-39 years and 40-44 years. Outcomes were defined as total mortality, CVD mortality 
(i.e. fatal CAD or stroke), total CVD (i.e. Fatal CAD or stroke, myocardial infarction, nonfatal 
stroke, or hospitalized coronary artery bypass graft or angioplasty), ACC/AHA CVD (i.e. Fatal 
CAD or stroke, nonfatal myocardial infarction, nonfatal stroke), and total CAD (i.e. Total CVD 
excluding fatal/nonfatal stroke).   
To quantify the excess risk of total mortality, CVD mortality, CVD, and CAD incidence 
in the EDC cohort, the expected number of events for each age group was calculated by 
multiplying the person-years at risk in the EDC cohort by the mortality and CVD and CAD 
incidence rates in the background Allegheny County population. Standardized mortality (SMR) 
and incidence rate ratios (IRR) were calculated, as appropriate, as the ratio of the observed 
number of events in EDC to the expected number of events. Due to the hospitalization data for 
the background Allegheny County population being restricted to 2004 to 2010, comparisons to 
the general population were carried out by restricting the EDC data to participants who were <45 
years old between 2004-2010 and performing a comparison of their CVD rates to the 2004-2010 
Allegheny County data. Finally, to address the possibility of survivor bias in the EDC data, a 
sensitivity analysis was performed in which all mortality and CVD events occurring between age 
30 and 44 ascertained during the complete 1986-2012 EDC study follow-up were included. 
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Statistical analyses were performed using SAS version 9.3 (SAS Institute Inc. Cary, NC) and the 
Open Source Epidemiologic Statistics for Public Health (OpenEpi) calculators (177). 
2.4 RESULTS 
Of the 391 participants who contributed follow-up between ages 30-39 during 1996-
2012, 5.6% (22) had at least one CVD event and 4.6% died during the 1996-2012 follow-up 
period. Of the 474 participants contributing follow-up between ages 40-44, 8.9% (n=42) had at 
least one CVD event and 5.1% (n=24) died. Participant characteristics by age group at the 1996-
1998 baseline examination are shown in Table 1. In both age groups, those who had CVD events 
and who died were significantly more likely to have hypertension, be using blood pressure-
lowering therapy, and have higher albumin excretion rates. Current smoking was significantly 
associated with CVD in those aged 30-39 and mortality in those aged 40-44. LDL-cholesterol 
was associated with CVD in those aged 30-39, but not in those 40-44 years old. HbA1c did not 
differ significantly in either age group by mortality or CVD status. 
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Table 1. Baseline (1996-1998) Characteristics by 1996-2012 Total Mortality and Cardiovascular Disease (CVD) Event Status 
Age 
Group1 
Characteristic Overall Died during 
follow-up 
Alive through 
follow-up 
p-value CVD Event No CVD p-value
30-39 Total n (n with clinical data) 391 (260) 18 (10) 373 (252) 22 (14) 369 (246) 
Diabetes Duration (yrs) 25.1 (5.0) 24.8 (5.2) 25.1 (5.0) 0.77 25.3 (5.5) 25.1 (5.0) 0.81 
Female Sex2 49.4% (193) 66.7% (12) 48.5% (181) 0.13 50.0% (11) 49.3% (182) 0.95 
HbA1c (%) 8.4 (1.4) 8.5 (0.8) 8.4 (1.5) 0.93 9.0 (1.5) 8.4 (1.4) 0.13 
LDL-cholesterol (mg/dl) 116.4 (31.2) 122.0 (35.4) 116.2 (31.1) 0.59 132.9 (37.1) 115.3 (30.6) 0.03 
HDL-cholesterol (mg/dl) 53.3 (13.6) 61.0 (22.6) 53.0 (13.1) 0.29 50.9 (14.5) 53.4 (13.6) 0.48 
Triglycerides (mg/dl)3 94 (66-144) 94 (73-180) 94 (66-143) 0.76 139 (82-180) 93 (66-132) 0.04 
Lipid-Lowering Therapy2 5.1% (19) 13.3% (2) 4.8% (17) 0.18 14.3%(3) 4.6% (16) 0.08 
Hypertension2 25.8% (76) 50.0% (9) 24.6% (69) 0.05 52.6% (11) 23.9% (66) 0.006 
Blood Pressure-Lowering 
Therapy2 
18.6% (68) 39.0% (7) 17.7% (62) 0.04 47.6% (10) 16.9% (58) <.0001 
Albumin Excretion Rate 
(µg/min)3 
11.5 
(5.8-77.4) 
310.6 
(209-1717) 
10.7 
(5.6-56.8) 
0.0002 296.7 
(18.9-1369) 
10.5 
(5.6-50.2) 
0.0004 
Current Smoker2 19.8% (73) 25.0% (4) 19.6% (69) 0.53 38.1% (8) 18.7% (65) 0.04 
40-44 Total n (n with clinical data) 474 (318) 24 (9) 450  (310) 42 (25) 432 (293) 
Diabetes Duration (yrs) 27.5 (6.2) 29.0 (5.7) 27.4 (6.2) 0.21 28.3 (5.9) 27.4 (6.3) 0.35 
Female Sex2 49.4% (234) 41.7% (10) 49.8% (224) 0.44 40.5% (17) 50.2% (217) 0.23 
HbA1c (%) 8.4 (1.5) 8.7 (1.6) 8.4 (1.5) 0.39 8.6 (2.1) 8.3 (1.4) 0.06 
LDL-cholesterol (mg/dl) 118.2 (31.2) 109.5 (28.6) 118.4 (31.3) 0.45 122.9 (31.0) 117.8 (31.2) 0.47 
HDL-cholesterol (mg/dl) 53.8 (14.0) 61.1 (25.5) 53.6 (13.5) 0.41 55.5 (17.3) 53.7 (13.7) 0.54 
Triglycerides (mg/dl)3 90 (66-129) 114 (73-125) 89 (66-129.5) 0.36 99.5 (76-154) 89 (66-126) 0.22 
Lipid-Lowering Therapy2 5.8% (26) 15.8% (3) 5.3% (23) 0.09 10.5% (4) 5.3% (22) 0.26 
Hypertension2 31.7% (115) 62.5% (10) 30.3% (105) 0.007 50.0% (17) 29.8% (98) 0.02 
Blood Pressure-Lowering 
Therapy2 
23.0% (102) 47.4% (9) 21.9% (93) 0.02 42.1% (16) 21.2% (86) 0.003 
Albumin Excretion Rate 
(µg/min)3 
12.5 
(5.7-57.2) 
81.8 
(34.8-527.8) 
11.0 
(5.6-51.6) 
0.003 42.0 
(14.4-201.3) 
10.7 
(5.6-50.9) 
0.006 
Current Smoker2 17.3% (77) 42.1% (8) 16.2% (69) 0.009 25.6% (10) 16.5% (67) 0.15 
Values are mean (SD) unless noted.  1Participant included in an age group if contributed any follow-up within the age range, 2 %(n), 3 median (interquartile range) 
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2.4.1 Total and CVD Mortality 
Age-matched comparisons of total mortality and CVD mortality between the EDC 
and the background Allegheny County population are presented in Table 2. Total mortality 4.6 
times higher than background in the 30-39 year age group (SMR 4.6, 95% CI 2.8, 7.2) 5.4 
times higher in the 40-44 year age group (SMR 5.4, 95% CI 3.6, 8.0). In both age groups, 
relative increase in mortality was greater in women than in men (Table 2). CVD mortality 
showed greater relative increases than total mortality in both age groups (age 30-39:  SMR 95% 
CI 16.9, 59.4, age 40-44: SMR 20.6, 95% CI 11.9, 33.1) and women again had relative 
increases than men. 
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Table 2. Total and Cardiovascular (CVD) Mortality Rates by Age and Sex in the in Epidemiology of Diabetes Complications (EDC) Study Cohort 
Compared to the Background Allegheny County Population (1996-2012) 
1Fatal coronary artery disease or stroke 
EDC Study Cohort (1996-2012) Allegheny County (1996-2012) 
Event Age and Sex Events Person Years 
Rate per 100,000 
(95% CI) Events 
Person 
Years 
Rate per 100,000
(95% CI) 
SMR 
(95% CI) 
Total 
Mortality 30-39 17 2,705 628 (379, 984) 3,817 2,765,085 138 (134, 142) 4.6 (2.8, 7.2) 
Men 1,352 444 (180, 920) 2,537 1,354,618 187 (180, 195) 2.4 (0.97, 5.0) 
Women 11 1,353 813 (428, 1409) 1,280 1,410,467 91 (86, 96) 9.2 (4.8, 15.9) 
40-44 24 1,910 1257 (826, 1835) 3,590 1,551,328 231 (224, 239) 5.4 (3.6, 8.0) 
   Men 14 998 1403 (800, 2287) 2,266 750,841 302 (289, 314) 4.7 (2.7, 7.6) 
Women 10 912 1096 (558, 1946) 1,324 800,487 165 (157, 174) 6.7 (3.4, 11.9) 
CVD 
Mortality1 30-39 10 2,705 370 (188, 658) 312 2,765,085 11 (10, 13) 33.3 (16.9, 59.4) 
   Men 4 1,352 296 (94, 712) 213 1,354,618 16 (14, 18) 18.5 (5.9, 44.7) 
Women 6 1,353 443 (180, 920) 99 1,410,467 7 (6, 8) 63.4 (25.7, 131.8) 
40-44 15 1,910 785 (457, 1263) 583 1,551,328 38 (35, 41) 20.6 (11.9, 33.1) 
Men 9 998 902 (441, 1648) 412 750,841 55 (50, 60) 16.4 (8.0, 30.0) 
Women 6 912 658 (267, 1363) 171 800,487 21 (18, 25) 31.6 (12.8, 65.7) 
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2.4.2 CVD Incidence Rates 
CVD incidences rates in young adults with T1DM are shown in Table 3. Using the 
CVD definition, which includes hospitalized revascularization procedures, young adults in aged 
30-39 had a CVD rate of 961 events per 100,000 person years (95% CI 643, 1385) those
aged 40-44 had a rate of 2,356 events per 100,000 (95% CI 1744, 3113). If the ACC/AHA 
definition of CVD, which does not include revascularization procedures, is used, the 
decrease to 628 events per 100,000 person years  (95% CI 379, 984) in those aged 30-1,518 
events per 100,000 person years (95% CI 1038, 2145) in those aged 40-44. For CAD
(which includes hospitalized revascularizations) those aged 30-39 had a rate of 850 per 100,000 
person years (95% CI 553, 1253), while the rate for those aged 40-44 was 2,042 per 100,000 
(95% CI 1476, 2753).   
Age-matched IRRs of CVD rates between young adults in the EDC cohort and 
background Allegheny County population during 2004-2010 are presented in Figure 
absolute CVD rates are presented in Table 4). EDC participants aged 30-39 had a total CVD of 
599 per 100,000 person years (95% CI 190, 1438), which is 8 times higher than the 
Allegheny County (95% CI 2·5, 19·3). Those aged 40-44 had a rate of 1,821 per 100,000 years 
(95% CI 1040, 2964), which is also approximately 8 times higher than the background 
(Rate Ratio (RR) 7.8, 95% CI 4.4, 12.7). If revascularization procedures are excluded, and 
ACC/AHA CVD definition is used, the rate for EDC participants aged 30-39 decreases 
per 100,000 person years (95% CI 50, 986), and is no longer significantly increased 
background (RR 5.0, 95% CI 0.8, 16.5). 
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Table 3. Cardiovascular Disease (CVD) Incidence Rates by Age and Sex in the 
Epidemiology of Diabetes Complications Study 1996-2012 
Event Age and 
Sex Events 
Person 
Years 
Rate per 100,000 
(95% CI) 
Total CVD 30-39 26 2,705 961 (643, 1385) 
Men 14 1,352 1036 (591, 1690) 
Women 12 1,353 887 (481, 1503) 
40-44 45 1,910 2356 (1744, 3113) 
Men 27 998 2705 (1827, 3858) 
Women 18 912 1974 (1211, 3041) 
ACC/AHA CVD 30-39 17 2,705 628 (379, 984) 
Men 8 1,352 592 (275, 1121) 
Women 9 1,353 665 (325, 1217) 
40-44 29 1,910 1518 (1038, 2145) 
Men 19 998 1904 (1184, 2903) 
Women 10 912 1096 (558, 1946) 
CAD 30-39 23 2,705 850 (553, 1253) 
Men 14 1,352 1036 (591, 1690) 
Women 9 1,353 665 (325, 1217) 
40-44 39 1,910 2042 (1476, 2753) 
Men 24 998 2405 (1583, 3503) 
Women 15 912 1645 (959, 2638) 
For those aged 40-44, using the ACC/AHA CVD definition reduced the rate to 650 per 
100,000 person years (95% CI 238, 1435), which is 4 times higher than background (95% CI 1.4, 
8.7). For CAD alone, EDC participants aged 30-39 had 12-fold higher risk than background (RR 
11.8, 95% CI 3.7, 28.4), while those aged 40-44 had 8-fold higher risk (RR 8.3, 95% CI 4.4, 
14.5). Again, for all definitions and both age groups, women in the EDC cohort had higher 
relative increases in risk over background compared to men, despite men having higher absolute 
risk. 
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2.4.3 Sensitivity Analysis 
When the estimates for total mortality and total CVD events were repeated including the 
entire 1986-2012 follow-up, EDC participants aged 30-39 had 10-fold greater total mortality 
(95% CI 7.2, 13.5) and 22-fold greater CVD incidence (95% CI 17.1, 28.2) than background. In 
those aged 40-44, EDC participants had 9-fold higher mortality (95% CI 6.3, 11.7) and 13-fold 
greater CVD incidence (95% CI 10.0, 16.1) than background.  
Figure 2.  Inicidence rate ratios for the Epidemiology of Diabetes Complications Study cohort compared to 
the background Allegheny County population, 2004-2010 
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2.5 DISCUSSION 
These results demonstrate that for a contemporary cohort of young adults <45 years old 
with long duration T1DM, total mortality, CVD mortality, and hospitalized CVD events are still 
significantly increased compared to the age-matched background population. Total mortality was 
increased approximately 5-fold, while CVD mortality was increased 20- to 30-fold. Hospitalized 
CVD events were increased 8-fold, with revascularization procedures accounting for much of the 
increased risk. If revascularization procedures are excluded, CVD risk was increased 4- to 5-fold. 
For CAD alone, the increase in risk was even larger than for CVD, at 8 to 11 times that of 
background. For all outcomes, the relative risk in women was larger than for men. 
2.5.1 Relative Risk of Mortality 
The excess risk of mortality associated with T1DM in the current analyses is consistent 
with prior reports. A recent systematic review of 23 reports on population-based T1DM cohorts 
concluded that T1DM is associated with excess mortality worldwide (49). The magnitude of 
excess risk varied widely, from no excess in a small cohort from Iceland (178) to an estimated 
8.5-fold excess in a cohort from Cuba (179). In a 2010 report from Allegheny County, 
Pennsylvania, a 6-fold greater mortality than the age-matched general population was observed 
by 20 years of diabetes duration (180).     
More recently, the Scottish Registry Linkage Study reported age-specific mortality and 
CVD rates (51). Total mortality for men aged 30-39 years with T1DM was 3.4 times that of the 
general population, while it was 5.2 times that of the general population for women in the same 
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age group. The SMR for total mortality in women 30-39 years old was markedly higher here in 
the EDC cohort at 9.2. In the Scottish report, the T1DM population aged 40-49 years had 4 and 
4.7 times higher mortality than the general population for men and women, respectively. These 
increases were again somewhat lower than seen here in the EDC cohort, but as our data 
examined those 40-44 years old, these results are not directly comparable. It is also important to 
note that at any given age, the EDC cohort represents a longer duration of diabetes than the 
Scottish Registry Linkage Study. The Scottish registry includes adult-onset cases of T1DM, and 
thus the median diabetes duration of 17.5 years at baseline is significantly shorter than that of the 
EDC cohort (26.6 years), which is restricted to exclusively childhood-onset (<17 years old) 
T1DM. This difference in the length of exposure to T1DM may explain the lower excess 
mortality seen in the Scottish study. 
Another recent report, from the Swedish National Diabetes Register, showed that even 
for patients with T1DM who had on-target glycemic control for the past 8 years, both total and 
cardiovascular mortality were increased compared to the general population (52). When 
examined by age and sex, regardless of glycemic control, the study reported that men between 
18-49 years old had 3- to 4-fold greater total mortality compared to the general population, while
women in the same age range had more than 4-fold greater total mortality. Relative increases 
were larger for deaths due to cardiovascular causes in both sexes, but especially for women, 
where CVD mortality was more than 7 times that of the general population. These relative 
increases are again lower than those reported here for young adults in the EDC cohort, 
particularly for CVD mortality. As in the Scottish Registry Linkage Study, however, the Swedish 
National Diabetes Register includes adult-onset cases of T1DM, so again, the average diabetes 
duration of 20.4 years is shorter than that of the EDC cohort, and may at least partially explain 
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the lower excess mortality.  In a separate report on data from the Swedish National Diabetes 
Register, life expectancy between the time periods of 2002-2006 and 2007-2011 was found to 
have increased by approximately two years in men but was unchanged in women (181). 
In a population-based study from Australia during two time periods, 1997-2003 and 
2004-2010, T1DM was also consistently associated with increased total mortality across both 
sexes and all age groups, except in children <10 years old (182). For men, the SMR was 4.1 in 
both time periods for those 30-39 years and 4.7 and 4.4, respectively, for those aged 40-49 years 
in each time period. For women, SMRs were 4.6 and 5 in those aged 30-39 years and 4.7 and 4.2 
in those aged 40-49. Total and CVD mortality in the source population declined significantly 
between 2000 and 2011 (53), with similar trends by sex. The SMRs for total mortality that we 
report here for the EDC cohort are comparable to the Australian report for men, but are markedly 
higher in women. The higher relative mortality observed in women was also shown in the 2010 
report from the Allegheny County T1DM Registry (180). As noted in that report by Secrest et 
al., it may not be appropriate to directly compare differences in SMR due to variation in 
methodology or characteristics across the populations. The higher relative mortality observed in 
women in the EDC cohort and the Allegheny County T1DM Registry compared to the other 
populations discussed may reflect differences in access to health care across countries, but this 
hypothesis is difficult to assess. The higher relative risk for women was also noted in a recent 
meta-analysis of 26 T1DM studies published between 1966 and 2014, where the excess risk of 
all-cause mortality associated with T1DM was 37% higher in women than in men when pooled 
across studies (50).  Interestingly, in a DCCT-eligible subgroup of EDC participants, the 
mortality rate of 363 per 100,000 (95% CI 202, 604) is very similar to the rate of 346 per 
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100,000 (95% CI 272, 440) observed in the DCCT conventional treatment arm (54), lending 
support to the generalizability of the DCCT data in the United States.  
2.5.2 Relative Risk of Cardiovascular Disease 
Our finding that young adults with T1DM remain at increased risk of CVD is also 
consistent with other recent reports. In the Scottish Registry Linkage Study, men and 
women with T1DM aged 20-39 years had CVD risk 4.8 and 5.5 times that of the general 
population, respectively (51). The sex difference was larger for those aged 40-49 years, 
where men with T1DM had 3.1 times the risk of the general population, while women with 
T1DM had greater than 5 times the risk. The sex difference we observed in the EDC cohort 
supports the finding that women with T1DM have greater excess CVD risk than men, but the 
excess was larger than seen in the Scottish study (51). The aforementioned meta-analysis by 
Huxley et al. reported that the sex difference was more extreme for CAD incidence than it 
was for mortality (50), which is consistent with our findings. In the pooled results from the 
meta-analysis, women with T1DM were >13 times more likely to have a CAD event than 
women without diabetes, while men with T1DM were approximately 6 times more likely to have 
a CAD event (50).  It has been suggested that the effect of hyperglycemia and diabetes on 
vascular risk is greater in women then in men, possibly due to poorer glycemic control in 
women (50,183). However, Colhoun et al. also reported that the greater excess risk in 
women with T1DM was not explained by a worse CVD risk factor profile for women 
compared to men (184). In an earlier report from the EDC study, depressive symptomatology 
was found to be associated with CAD incidence in women, but not 
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in men, suggesting that nontraditional risk factors may explain the excess CVD risk in women 
and merit further exploration (56).    
A comparison of the relative risk estimates reported across countries can be found in 
Appendix B. 
2.5.3 Absolute Risk of Cardiovascular Disease 
Despite this consistent evidence that young adults with T1DM are at increased risk of 
CVD mortality and morbidity, treatment guidelines are based on extrapolations from data on 
type 2 diabetes and the general population due to a lack of trial data in T1DM. The validity of 
using these extrapolations has been questioned (185). The 2013 ACC/AHA guidelines 
recommend high-intensity statin therapy in individuals between ages 40-75 years with diabetes 
and a ≥7.5% estimated 10-year risk of CVD (73). In these analyses of the EDC cohort, young 
adults 40-44 years old had a 10-year ACC/AHA definition CVD risk of 15.2%. The guidelines 
state that, in individuals with diabetes who are younger than 40 years, the decision to begin statin 
therapy should be individualized (73). Here, in the EDC cohort, young adults 30-39 years old 
had a 6.3% 10-year CVD risk (ACC/AHA definition), which approaches, but is slightly below, 
the recommended cut-point of 7.5%. However, three additional CVD events occurred in the 30-
39 year old age group prior to the 1996 baseline used in these analyses and approximately 5% of 
30-39 year olds in the EDC were already on lipid-lowering medication at baseline (Table 1), with
the proportion rising to >20% by 2012 (data not shown). Thus, it is likely that the 10-year CVD 
risk would exceed 7.5% if it were possible to include the prevalent cases and account for existing 
lipid-lowering therapy.   Additionally, if hospitalized revascularization procedures are included 
in the CVD definition, the 10-year risk in 30-39 year olds increases to 9.6%. These results 
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suggest that CVD risk in young adults with T1DM duration >20 years who are between 30-39 
years old is most likely high enough to merit the use of statin therapy, given current ACC/AHA 
thresholds. Furthermore, a recent report has suggested that an individualized approach to statin 
therapy may be more appropriate, which would further justify statin use in this group of T1DM 
patients (186).  The importance of glycemic control in preventing CVD events remains a critical 
question.  Here, while CVD cases did have higher levels of HbA1c at baseline, the difference did 
not reach statistical significance. Interestingly, in an examination of CVD risk factors from the 
DCCT/EDIC study, updated weighted-mean HbA1c was found to be a strong predictor of CVD 
incidence, second only to age, while LDL-cholesterol was a significant, but weaker predictor 
(187). These results stress the need for intensive glycemic control, in addition to lipid-lowering 
therapy, to prevent CVD events. 
A comparison of the absolute risk estimates reported across countries can be found in 
Appendix B. 
2.5.4 Strengths and Limitations 
Our study has noted strengths. The Pittsburgh EDC is a well-characterized cohort with 
nearly thirty years of prospective follow-up to date. Deaths and CVD events were verified using 
death certificates, interviews with next of kin, autopsy reports, and medical records and classified 
by a committee of physicians using all available information.  The limitations include the 
potential for “survivor bias” due to deaths occurring prior to the 1996-2012 follow-up period of 
interest here. This issue may lead to an underestimation of the CVD risk of the EDC cohort, as 
the highest risk participants may have died prior to the beginning of follow-up. We have 
attempted to assess this possibility by performing a sensitivity analysis, which includes all deaths 
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and CVD events that occurred in young adults <45 years old during the entire 1986-2012 follow-
up of the EDC cohort. These estimates provide an upper limit to the excess mortality and CVD 
risk in these young adults. Another limitation of these analyses is the restricted availability of 
CVD hospitalization data from the background population to 2004-2010. Also, using the 
available data set from Allegheny County, it is not possible to identify which individuals in the 
background population data have T1DM which, in addition to the EDC participants who are 
already using lipid-lowering therapy, leads to a potential underestimation of the relative 
increased risk of the EDC cohort. Finally, these data are from a cohort of people from 
Southwestern Pennsylvania and may not reflect the experience of all young adults with T1DM in 
the United States. Also, the EDC is a hospital-based cohort, which may restrict the 
generalizability of these results. However, it has previously been shown that the epidemiologic 
characteristics (167) and the mortality experience (188) in the hospital-based EDC cohort closely 
reflects that of the population-based Allegheny County T1DM cohort for participants who were 
diagnosed during the same period. 
In conclusion, total mortality, CVD mortality, and hospitalized CVD events remain 
significantly increased in this US contemporary cohort of young adults <45 years old with long-
duration T1DM, compared to the background population. As has been consistently demonstrated 
across international studies, the relative increase in risk is greater for women than for men. These 
findings support the need for more aggressive CVD risk factor management particularly in 
women with T1DM.   
43
Table 4.  Comparison of Cardiovascular Disease (CVD) Incidence Rates by Age and Sex between the Epidemiology of Diabetes 
Complications (EDC) Study and Background Allegheny County Population (2004-2010) 
EDC Study Cohort (2004-2010) Allegheny County (2004-2010) 
Event Age and Sex Events Person Years 
Rate per  
100,000 (95% CI) Events 
Person 
Years 
Rate per 100,000 
(95% CI) 
Rate Ratio 
(95% CI) 
Total CVD 30-39 4 668 599 (190, 1438) 797 1,032,759 77 (72, 83) 8.0 (2.5, 19.3) 
Men 2 307 651 (109, 2135) 501 505,822 99 (90, 108) 6.7 (1.1, 22.0) 
Women 2 361 554 (93, 1818) 296 526,937 56 (50,63) 10.0 (1.7, 33.0) 
40-44 14 769 1,821 (1040, 2964) 1,411 604,102 234 (221, 246) 7.8 (4.4, 12.7) 
Men 5 390 1,282 (471, 2818) 934 291,303 321 (300, 341) 4.0 (1.5, 8.9) 
 Women 9 379 2,375 (1164, 4313) 477 312,799 152 (139, 166) 15.8 (7.7, 29.0) 
ACC/AHA 
CVD 
30-39 2 668 229 (50, 986) 635 1,032,759 61 (57, 66) 5.0 (0.8, 16.5) 
Men 0 307 - 383 505,822 76 (68, 83) - 
 Women 2 361 554 (93, 1818) 252 526,937 48 (42, 54) 11.8 (2.0, 38.9) 
40-44 5 769 650 (238, 1435) 1,001 604,102 166 (155, 176) 3.9 (1.4, 8.7) 
Men 3 390 769 (196, 2079) 619 291,303 212 (196, 229) 3.8 (0.9, 10.2) 
 Women 2 379 528 (88, 1732) 382 312,799 122 (110, 134) 4.3 (0.7, 14.4) 
CAD 30-39 4 668 599 (190, 1438) 524 1,032,759 51 (46, 55) 11.8 (3.7, 28.4) 
Men 2 307 651 (109, 2135) 376 505,822 74 (67, 82) 9.1 (1.5, 30.0) 
 Women 2 361 554 (93, 1818) 148 526,937 28 (24, 33) 20.0 (3.4, 66.1) 
40-44 11 769 1,430 (755, 2472) 1,036 604,102 171 (161, 182) 8.3 (4.4, 14.5) 
Men 4 390 1,026 (327, 2455) 768 291,303 263 (245, 282) 3.9 (1.2, 9.4) 
 Women 7 379 1,847 (811, 3619) 268 312,799 86 (75, 96) 21.9 (9.6, 43.3) 
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3.0  RISK STRATIFICATION FOR 25-YEAR CARDIOVASCULAR DISEASE 
INCIDENCE IN TYPE 1 DIABETES:  TREE-STRUCTURED SURVIVAL 
ANALYSIS
3.1 ABSTRACT 
-year 
The formal identification of high risk subgroups, though clinically useful, is generally 
undertaken in observational cohort studies of cardiovascular disease (CVD).  Tree-
strucured survival analysis (TSSA) was utilized to determine whether there are meaningful 
subgroups varying levels of CVD risk in the Pittsburgh Epidemiology of Diabetes 
Complications study, a prospective cohort study of childhood-onset (<17 years old) type 1 
diabetes. Of the participants free of CVD (defined as the first instance of coronary artery 
disease, stroke, or extremity arterial disease) at baseline, 263 (46.9%) had an incident CVD 
event over the 25 follow-up.  TSSA revealed a range of risk groups, from 24 to 85%, 
which were define combinations of diabetes duration, non-HDL-cholesterol, albumin 
excretion rate (AER), white blood cell count.  Interestingly, those with short duration 
diabetes but elevated cholesterol had similar risk to long duration diabetes, while major sex 
differences were appa for long diabetes duration participants.  Our findings suggest that 
subgroups with major risk differences exist in this cohort of childhood-onset type 1 diabetes.  
Further study, inc external validation, is needed to better determine the prognostic utility of 
TSSA for CVD management. 
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3.2 INTRODUCTION 
As in the general population, cardiovascular disease (CVD) is a major contributor to 
morbidity and mortality in individuals with type 1 diabetes, however the risk of CVD is greatly 
increased (55,65–67).  The reasons for this increased risk are not fully understood, as the 
hyperglycemia that characterizes type 1 diabetes has been an inconsistent predictor of CVD 
incidence across studies (57–64,189). Notably, the gender difference in CVD incidence observed 
in the general population seems to be narrowed in type 1 diabetes, so that women have nearly the 
same risk as men (56,68). 
There is evidence to support the existence of important subgroups with respect to CVD 
incidence and risk factors in type 1 diabetes.  While nephropathy is considered a major risk 
factor for CVD in type 1 diabetes (83–86), this relationship is also not well understood.  In some 
cases, adjusting for the traditional cardiovascular risk factors that are potential confounders or 
mediators of the renal-CAD link does attenuate the relationship (60).  Nephropathy may also 
affect the presentation of CAD, such that individuals with nephropathy are more likely to present 
with a “harder” or more severe event, like a myocardial infarction (63).  Additionally, though 
nephropathy was found to be a stronger risk factor for CAD in men than in women in the 
Pittsburgh Epidemiology of Diabetes Complications (EDC) study (56), in the Eurodiab study 
nephropathy predicted CAD incidence in both sexes (61).  Although the risk of developing CVD 
is approximately equivalent by sex in type 1 diabetes, there is evidence that the risk factors for 
CVD differ in men and women.  Besides the aforementioned sex difference in the relationship 
between CAD and nephropathy, smoking may be a stronger risk factor for CAD in men, while 
depressive symptomatology and less physical activity appear to predict CAD more strongly in 
women (56).   
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Formal identification of important subgroups is not often undertaken in observational 
cohort studies of CVD. Utilizing methodology to formally identify subgroups at varying levels of 
risk may reveal relationships between risk factors and outcomes that are not detected using usual 
methods, such as comparing means, which assesses aggregate data, or regression, which 
generally assumes a constant increasing risk of an outcome for each unit increment of a risk 
factor.  Neither of these commonly used approaches accounts for potential heterogeneity within 
the group being studied, the possibility of complex higher-order interactions between risk factors 
(115), or a potential non-linearity or threshold effect of a risk factor on the outcome of interest 
(146). Even when identification of subgroups is attempted, interactions between groups are often 
not assessed because it is cumbersome to do so with traditional regression techniques (135,146).  
Studies where decision tree methods have been utilized demonstrate the potential importance of 
such an approach in identifying CVD risk groups (115,116,190).  Decision tree analysis of the 
Western Collaborative Group Study data identified different groups of men, based on 
interactions between obesity, age, and hypertension status, who were at very high risk of 
coronary heart disease mortality (115).  Also, in an earlier exploration of the Pittsburgh EDC 
study, decision tree methods were used to identify subgroups of participants who were at low 
risk for diabetes complications based on biologic risk factors.  Genetic markers were then 
examined within the lowest risk groups identified by the trees and, using this approach, 
associations between the genes and complications emerged that were not observed in the overall 
study population (116).  These examples demonstrate that decision trees offer advantages to 
epidemiologic research and may reveal relationships between risk factors and outcomes that 
would otherwise remain undetected.  Additionally, the resulting trees are potentially well suited 
for clinical applications, as they are presented in a manner that is often similar to the medical 
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decision-making process (135,146). Thus, we used tree-structured survival analysis, a 
hierarchical decision tree method that can accommodate time-to-event outcomes, to determine 
whether there are meaningful subgroups at varying levels of CVD risk in the Pittsburgh EDC 
study.  In addition to total CVD, specific manifestations of CVD, including CAD, stroke, lower 
extremity arterial disease, and fatal CAD and stroke events were assessed as separate outcomes 
to explore whether differences in subgroups and higher-order interactions would emerge. 
3.3 METHODS 
3.3.1 Study population 
The Pittsburgh EDC Study is a prospective cohort study of childhood-onset (<17 years 
old) type 1 diabetes. All participants were diagnosed, or seen within 1 year of diagnosis, at 
Children’s Hospital of Pittsburgh between 1950 and 1980.  The cohort has been described in 
detail elsewhere (167,191).  In brief, participants have been followed since 1986-1988, initially 
with biennial examinations and questionnaires for 10 years and thereafter with biennial 
questionnaires and further examinations at 18 and 25 years post-baseline.  Research protocols 
were approved by the University of Pittsburgh institutional review board and all participants 
provided written informed consent. 
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3.3.2 Ascertainment of cardiovascular outcomes 
Participants were followed for 25 years to assess the incidence of total cardiovascular 
disease (CVD), defined as the first instance of coronary artery disease (CAD) (i.e. fatal CAD, 
myocardial infarction, revascularization procedure, blockage ≥50%, ischemic ECG, or angina), 
stroke, or lower extremity arterial disease (LEAD - Ankle brachial index (ABI) <0.8, lower limb 
amputation due to vascular cause, or intermittent claudication).  Fatal events were ascertained 
using medical records, death certificates, autopsy reports, and/or interview with next of kin and 
classified according to the Diabetes Epidemiology Research International (DERI) system (169).  
Myocardial infarction, revascularization/blockage, and stroke were self-reported by the study 
participants and confirmed by medical records.  Amputation was ascertained by self-report 
and/or physician examination.  ABI was determined using a Doppler blood-flow detector with 
the subject supine and ratios for each of the right and left tibialis posterior and doralis pedis 
systolic pressures were calculated with arm systolic pressure as the denominator. Intermittent 
claudication was assessed using the Rose questionnaire (192).   In addition to total CVD, the 
following alternative outcomes were assessed: total CAD, stroke, LEAD, and CVD mortality 
(CAD death, fatal MI, or fatal stroke).  Participants with prevalent CVD at baseline were 
excluded from analyses of the corresponding analyses outcome. 
3.3.3 Risk Factor Assessment 
Fasting blood samples were taken to measure HbA1, lipids, lipoproteins, serum 
creatinine, and serum albumin.  HbA1 values were converted to DCCT-aligned values using a 
regression equation derived from duplicate assays (DCCT HbA1c=0.14 + 0.83[EDC HbA1]) 
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(62).  Serum total cholesterol and triglycerides were determined enzymatically (170,171) and 
HDL cholesterol was determined using a modified precipitation technique (172) based on the 
lipid research clinics method (173).  Non-HDL cholesterol (non-HDLc) was calculated by 
subtracting HDL cholesterol from total cholesterol.  Three seated blood pressure readings were 
taken with a random-zero sphygmomanometer, and the mean of the second and third readings 
was used in analyses, according to the Hypertension Detection and Follow-Up protocol (175).  
Serum creatinine was measured using an Ectachem 400 Analyzer (Eastman Kodak Co.).  Pulse 
rate (beats/minute) was determined by palpitating the radial pulse for 30 seconds and multiplying 
by two. Serum and urinary albumin were measured by immunonephelometry (176).  Albumin 
excretion rate (AER) was calculated for each of three timed urine samples (24-hour, overnight, 
and 4-hour collections obtained over a two week period); the median of the three AERs was used 
in analyses. Glomerular filtration rate was estimated by the CKD-EPI creatinine equation (193).  
White blood cell count (WBC), red blood cell count, hemoglobin, and hematocrit were measured 
using a Coulter Counter S-Plus IV.  Fibrinogen was measured using the Biuret method.  
Participants were weighed in light clothing on a balance beam scale.  Height was measured using 
a wall-mounted stadiometer.  Body mass index (BMI) was calculated as the weight in kilograms 
divided by the square of the height in meters.  Waist circumference was measured twice at the 
midpoint between the highest point of the iliac crest and the lowest part of the costal margin in 
the midaxillary line. If the two measurements differed by >0.5 cm, a third measurement was 
performed. The mean of the waist measurements was recorded as waist circumference. Hip girth 
was measured at the widest point of the glutei, usually at the level of the greater femoral 
trochanter, and the mean of two measures was recorded as the hip circumference, in the same 
manner as the waist measurements. The ratio of the waist to hip circumference (WHR) was used 
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in analyses. Current smoking status was obtained by self-report.  Insulin dose was calculated by 
dividing units of insulin administered per day by body weight in kilograms.   
3.3.4 Tree-Structured Survival Analysis 
In 1984, Breiman et al. developed Classification and Regression Trees (CART), an 
algorithm which generated decision trees for continuous and categorical outcomes (139).  The 
general concept underlying decision tree construction is that attributes are split into subsets 
(nodes), each of which is homogeneous with respect to the outcome of interest.   Split points are 
based on values of attributes that maximize a criterion quantifying heterogeneity of outcomes 
among each of the daughter nodes.  The largest heterogeneity occurs in the initial split. 
Subsequent splits can be made on either the same or other attributes.  This hierarchical process is 
repeated recursively until all instances within a node are as homogenous as possible, with regard 
to outcome classification (140).    Traditionally, decision trees are used to derive subgroups for 
the prediction of a binary outcome.  However, in the 1980s and 90s, the decision tree framework 
was extended to accommodate time-to-event survival data with censored observations (141–
143).  Cross-validation is the most commonly used method for training and testing to find the 
best tree.  Rather than simply building a single tree and holding out a proportion of the data for 
testing, cross-validation is an iterative process which repeats the process several times on random 
samples that partition the data into n relatively equally sized subsets (n is usually 5 or 10) 
(140).  One of the subsets is dropped and the tree is refit.  This process is repeated for each of the 
other n-1 subsets and then error rates from the n fits are used to identify the best fitting and most 
parsimonious tree (144). 
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In our analyses, we used the rpart routine of R version 3.0.2 (R Development Team 2013) 
to fit decision trees to the EDC data for the time to CVD event outcome.  The rpart routine has 
been described in detail by Therneau and Atkinson (144).  Data from EDC participants who were 
free of CVD at baseline were included in these analyses (n=561).  The list of baseline variables 
made available for tree building is shown in Table 5.   A minimum of 15 observations in each 
child node was required for further splitting to be considered.  The complexity parameter 
corresponding to the minimum cross-validated error was chosen to prune the tree. Separate trees 
were also constructed for each manifestation of CVD outcome variable described above, in an 
attempt to identify subgroups and potentially important interactions between risk factors.  
Additionally, separate trees were constructed for men and women and for the two diabetes 
diagnosis subcohorts (1950-1964 versus 1965-1980).  We previously examined these two 
subcohorts and found that they have significantly different survival experiences (188).  
3.4 RESULTS 
Of the 561 participants free of CVD at baseline, there were 263 (46.9%) cases of incident 
CVD over the 25-year follow-up.  Participant characteristics at baseline are shown in Table 5.  
EDC participants who developed CVD over the 25 years of follow-up were significantly older, 
had longer diabetes duration, higher BMI, WHR, non-HDL cholesterol, triglycerides, systolic 
and diastolic blood pressures, pulse rate, WBC, serum creatinine, and AER, and lower serum 
albumin, eGFR, and insulin dose, and were more likely to be smokers.  
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Table 5.   Baseline Charateristics of the Pittsburgh EDC Cohort by 25-Year Total Cardiovascular Disease 
(CVD) Incidence Status (n=561 free of prevalent CVD at baseline) 
Characteristic CVD Incidence 
(n=263) 
No CVD 
(n=298) 
p-value
Age (years) 29.9 (7.4) 24.3 (7.0) <.0001 
Diabetes Duration (years) 21.5 (7.4) 16.2 (6.4) <.0001 
Female Sex, % (n) 49% (130) 49% (147) 0.98 
Non Caucasian, % (n) 1.9% (5) 2.4% (7) 0.78 
BMI (kg/m2) 23.8 (3.2) 23.3 (3.2) 0.04 
Waist-Hip Ratio 0.84 (0.07) 0.81 (0.07) <.0001 
HbA1c (%) 8.78 (1.50) 8.71 (1.53) 0.59 
HDL Cholesterol (mg/dl) 53.7 (12.6) 54.9 (12.0) 0.25 
Non-HDL Cholesterol (mg/dl) 146.5 (42.8) 122.7 (34.8) <.0001 
Triglycerides (mg/dl), median 
(IQR) 
88.5 (65-131) 75.0 (56-102) 0.005 
Systolic Blood Pressure (mmHg) 116.3 (16.2) 109.0 (11.4) <.0001 
Diastolic Blood Pressure (mmHg) 74.1 (11.6) 70.6 (9.6) 0.0001 
Blood Pressure Med Use, % (n) 14% (37) 3.2% (9) <.0001 
Pulse Rate (bpm) 79.5 (9.7) 76.8 (9.7) 0.001 
Hemoglobin (g/dl) 15.0 (1.7) 15.3 (1.5) 0.06 
White Blood Cell Count (x103/µl) 6.77 (1.97) 6.17 (1.56) <.0001 
Fibrinogen (mg/dl) 301.8 (97.8) 285.8 (126.5) 0.10 
Serum Albumin (g/dl) 4.58 (0.80) 4.73 (0.71) 0.02 
Serum Creatinine (mg/dl) 1.11 (1.18) 0.90 (0.61) 0.007 
Albumin Excretion Rate (µg/min), 
median (IQR) 
27.8 (8.8-406.3) 10.9 (6.3-28.7) <.0001 
Estimated Glomerular Filtration 
Rate (mL/min/1.73 m2) 
98.4 (33.2) 111.7 (28.4) <.0001 
Insulin Dose (units/kg body 
weight) 
0.77 (0.27) 0.81 (0.24) 0.08 
Ever smoker, % (n) 44% (115) 30% (89) 0.0007 
Current smoker, % (n) 26% (68) 19% (56) 0.05 
Values are mean (sd), unless noted 
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3.4.1 Total Cardiovascular Disease Decision Tree 
The best survival tree for total CVD incidence identified five distinct risk groups (Figure 
4).  The tree first split on diabetes duration at the selected cut-point of 20.9 years.  In those with 
diabetes duration <20.9 years, and thus low risk, the tree further split on non-HDLc at 132.5 
mg/dl (CVD incidence 24.2% below (Group A) and 50.4% above (Group B) the non-HDLc cut-
point).  In those with diabetes duration ≥20.9 years the tree first split on AER at a cut-point of 
91.7 µg/min and in those with AER<91.7 µg/min, a second split on WBC at 7.15 x103/µl is 
identified (CVD incidence 52.5% below (Group C) and 81.5% above (Group D) the WBC cut-
point).  Finally, in those defined by duration≥20.9 years and AER≥91.7 µg/min, the highest risk 
group had a CVD incidence of 85.2% (Group E).  Kaplan-Meier curves for the five groups 
confirmed the pattern of CVD incidence identified by the tree (Figure 5).  The baseline 
characteristics of the five groups identified by TSSA are shown in Table 6. 
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Figure 3.  Survival Tree for the 25-Year Incidence of Total Cardiovascular Disease in the Pittsburgh EDC 
Study Overall Cohort 
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Figure 4.  Kaplan Meier Survival Curves for the 25-Year Incidence of Total 
Cardiovascular Disease by Risk Groups Identified by Tree-Structured Survival Analysis 
aGroup A=Diabetes duration<20.9years, nonHDL-cholesterol<132.5mg/dl 
bGroup B=Diabetes duration<20.9years, nonHDL-cholesterol≥132.5mg/dl 
cGroup C=Diabetes duration≥20.9years, albumin excretion rate<91.7µg/min, white cell count 
<7.15 x103/µl 
dGroup D=Diabetes duration≥20.9years, albumin excretion rate<91.7µg/min, white cell count 
≥7.15 x103/µl 
eGroup E=Diabetes duration≥20.9years, albumin excretion rate≥91.7µg/min 
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Table 6.  Baseline Characteristics of the Five Pittsburgh EDC 25-Year Total Cardiovascular Disease (CVD) 
Risk Groups Identified by Tree-Structured Survival Analysis 
Characteristic Group A: 
24.2% 
CVDa 
Group B: 
50.4% 
CVDb 
Group C: 
52.5% 
CVDc 
Group D: 
81.5% 
CVDd 
Group E: 
85.2% 
CVDe 
Age (years) 22.3 (5.6) 23.9 (5.1) 33.3 (5.7) 37.0 (4.9) 33.3 (5.4) 
Diabetes Duration (years) 13.5 (3.9) 14.7 (3.7) 26.5 (3.8) 28.5 (3.7) 26.6 (4.2) 
Female Sex, % (n) 47% (106) 53% (69) 51% (51) 63% (17) 42% (34) 
Non Caucasian, % (n) 1.8% (4) 3.1% (4) 2.0% (2) 3.7% (1) 1.2% (1) 
BMI (kg/m2) 23.0 (3.3) 23.8 (3.2) 23.9 (2.9) 23.8 (3.3) 24.0 (3.3) 
Waist-Hip Ratio 0.81 (0.06) 0.83 (0.06) 0.82 (0.07) 0.85 (0.09) 0.85 (0.08) 
HbA1c (%) 8.55 (1.26) 9.50 (1.77) 8.16 (1.30) 9.02 (1.33) 8.77 (1.64) 
Insulin Dose (units/kg) 0.84 (0.23) 0.83 (0.25) 0.69 (0.19) 0.72 (0.27) 0.76 (0.31) 
HDL Cholesterol (mg/dl) 54.9 (11.3) 52.4 (11.4) 57.3 (13.7) 57.9 (12.5) 50.8 (13.2) 
Non-HDL Cholesterol 
(mg/dl) 
105.7 (16.6) 165.5 
(37.7) 
129.8 (35.0) 151.2 (32.9) 160.6 (43.4) 
Triglycerides (mg/dl), 
median (IQR) 
67.5 
(55-89) 
112 
(79-153) 
71 
(52-97) 
94.5 
(68.5-136) 
115 
(80-173) 
Systolic Blood Pressure 
(mmHg) 
107.5 (10.8) 111.3 
(12.4) 
112.4 (11.7) 115.6 (13.6) 126.6 (18.7) 
Diastolic Blood Pressure 
(mmHg) 
69.3 (10.0) 73.0 (9.2) 71.1 (8.5) 72.3 (9.4) 80.6 (13.0) 
Blood Pressure Med Use, % 
(n) 
0.95% (2) 5.6% (7) 6.1% (6) 15% (4) 34% (27) 
Pulse Rate (bpm) 76.2 (9.8) 79.7 (8.8) 77.2 (8.3) 80.4 (11.1) 81.0 (11.0) 
Hemoglobin (g/dl) 15.3 (1.5) 15.4 (1.6) 15.0 (1.5) 14.7 (1.9) 14.8 (1.9) 
White Blood Cell Count 
(x103/µl) 
6.12 (1.58) 6.83 (1.70) 5.42 (0.92) 8.52 (1.50) 7.35 (2.25) 
Fibrinogen (mg/dl),  
median (IQR) 
250 
(210-300) 
280 
(240-360) 
250 
(210-310) 
300 
(240-330) 
320 
(275-382.5) 
Serum Albumin (g/dl) 4.71 (0.71) 4.64 (0.81) 4.82 (0.61) 4.50 (0.59) 4.43 (0.92) 
Serum Creatinine (mg/dl) 0.84 (0.29) 0.99 (1.12) 0.88 (0.27) 1.30 (1.75) 1.50 (1.51) 
Albumin Excretion Rate 
(µg/min), median (IQR) 
9.75 
(6.08-20.2) 
20.22 
(8.81-
168.6) 
11.07 
(6.51-23.6) 
12.36 
(6.94-39.4) 
830.6 
(291.1-1961.4) 
Estimated Glomerular 
Filtration Rate 
(mL/min/1.73 m2) 
114.8 (25.5) 112.0 
(32.6) 
102.6 (24.8) 91.6 (34.5) 77.5 (32.6) 
Ever smoker, % (n) 21% (48) 42% (54) 41% (41) 63% (17) 56% (45) 
Current smoker, % (n) 15% (34) 29% (37) 9.9% (10) 44% (12) 26% (32) 
aGroup A (n=223): Diabetes duration<20.9 yrs, nonHDL-cholesterol<132.5 mg/dl 
 bGroup B (n=129): Diabetes duration<20.9 yrs, nonHDL-cholesterol≥132.5 mg/dl 
 cGroup C (n=101): Diabetes duration≥20.9 years, albumin excretion rate<91.7µg/min, white cell 
count <7.15 x103/µl 
 dGroup D (n=27): Diabetes duration≥20.9 years, albumin excretion rate<91.7µg/min, white cell count 
≥7.15 x103/µl 
 eGroup E (n=81): Diabetes duration≥20.9 years, albumin excretion rate≥91.7µg/min 
Separate decision trees were also derived for total CVD incidence by sex and diabetes 
diagnosis subcohort (1950-1964 versus 1965-1980) (Figure 6). In women (panel A), the 25-year 
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incidence of CVD was 46.9% (130 cases) and the tree first split on diabetes duration at 17.6 
years. In lower risk women with diabetes duration <17.6 years, non-HDLc further discriminated 
CVD risk, with a chosen cut-point of 125.3 mg/dl (CVD incidence 13% below and 46% above 
cut-point).  In women with diabetes duration ≥17.6 years, no further discriminating factors were 
identified and the 25-year risk of CVD was 66%.  In men (panel B), there was a similar 46.8% 
(133 cases) 25-year incidence of CVD, but the tree first split on AER at 104.3 µg/min. In men 
with AER<104.3 µg/min, the tree split on non-HDLc.  Those with non-HDLc <133.2 mg/dl had 
a 24.1% 25-year risk of CVD, while in those with non-HDLc ≥133.2 mg/dl waist-hip ratio 
further discriminated risk (CVD incidence 0% below and 64.3% above cut-point). Men with 
AER ≥104.3 µg/min had the highest risk and the tree further split on diabetes duration at 26 
years (CVD incidence 65.2% below and 96.2% above cut-point).  
In the 1950-1964 subcohort (panel C), the 25-year incidence of CVD was 70.6% (120 
cases) and the tree split only on AER at 91.7 µg/min (CVD incidence 59.8% below and 88.9% 
above cut-point).  The 1965-1980 subcohort (panel D) had a 36.6% (143 cases) 25-year CVD 
incidence.  The tree first split on non-HDLc at 133.2 mg/dl. In those with non-HDLc <133.2 
mg/dl, the tree split on AER: those with AER <458 µg/min had 23.4% risk, while those with 
AER ≥458 µg/min had 71.4% risk. In those with non-HDLc≥133.2 mg/dl, diabetes duration 
further discriminated risk, such that those with duration <18.2 years had 44.3% risk and those 
with duration ≥18.2 years had 73.5% risk.   
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Figure 5.  Survival Trees for the 25-Year Incidence of Total Cardiovascular Disease By Sex 
and Type 1 Diabetes Diagnosis Cohort  
A)Women, B) Men, C) Type 1 Diabetes Diagnosed 1950-1964, D) Type 1 Diabetes Diagnosed
1965-1980
3.4.2 Specific Manifestations of Cardiovascular Disease 
The best fitting survival trees for the specific manifestations of CVD are shown in Figure 
7. The 25-year incidence of CVD death was 17.0% (112 deaths).  The tree for CVD mortality
(panel A) first split on AER: in those with AER<26.93 µg/min, diabetes duration further 
discriminated risk of CVD mortality at a cut-point of 23.09 years.  Diabetes duration was also 
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selected as the discriminating factor in those with AER ≥26.93 µg/min, but at a slightly lower 
cut-point of 21.95 years (Figure 7A).  
For CAD, the 25-year incidence was 34.7% (210 cases out of 605 free of CAD at 
baseline), with the first split on diabetes duration at the selected cut-point of 22.8 years (panel 
B).  In those with diabetes duration <22.8 years the tree further split on non-HDLc at 123.2 
mg/dl, while in those with diabetes duration ≥22.8 years the tree further split on AER at 131.9 
µg/min.   
The 25-year incidence of stroke was 6.7% (44 cases out of 654 free of stroke at baseline).  
The tree for stroke (panel C) first split on non-HDLc at 115.6 mg/dl.  In those with non-
HDLc<115.6 mg/dl, no further splits were selected, but in those with non-HDLc ≥115.6 mg/dl, 
stroke risk split on AER at 54.3 µg/min, with the lower AER group further splitting on WBC at 
9.2 x103/µl. 
The 25-year incidence of LEAD was 26.1% (157 cases out of 601 free of LEAD at 
baseline).  For LEAD (panel D), diabetes duration was chosen for the first split, such that with 
diabetes duration <21 years, the tree split on non-HDL cholesterol at 132.5 mg/dl.  Likewise, in 
those with diabetes duration ≥21 years, the tree also split on non-HDLc, but at a higher cut-point 
of 164.6 mg/dl. 
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Figure 6.  Survival Trees for the 25-Year Incidence of the Specific Manifestations of 
Cardiovascular Disease 
A) Cardiovascular Mortality, B) Coronary Artery Disease, C) Stroke, D) Lower Extremity
Arterial Disease
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3.5 DISCUSSION 
Tree-structured survival analysis of the EDC study data suggest that subgroups with 
major CVD risk differences exist in this cohort of childhood-onset type 1 diabetes over 25 years 
of follow-up and that these subgroups are identifiable by threshold effects of continuously 
measured risk factors measured only once at baseline.  A wide range of CVD risk was observed 
across the TSSA-identified subgroups, ranging from 24 to 85% over the 25-year follow-up.  
Though various combinations of diabetes duration, non-HDLc and/or AER generally 
discriminated risk for both total CVD and the specific manifestations of CVD, the identified 
optimal cut-points of the risk factors varied and WBC and waist-hip ratio also discriminated in 
some subgroups. 
For total CVD, five subgroups were identified through varying combinations of risk 
factors and they corresponded to three levels of CVD risk.  The lowest risk (24.2%) group was 
characterized by shorter diabetes duration/younger age and had a relatively good risk factor 
profile (Group A).  Two moderate risk groups were identified:  one with shorter diabetes 
duration/younger age and non-HDLc ≥132.5 mg/dl (Group B, CVD risk 50.4%) (Group B) and 
the other with longer diabetes duration/older age, but a relatively good risk factor profile (Group 
C, CVD risk 52.5%). The nearly equivalent 25-year CVD risk in these two groups suggests that 
moderate dyslipidemia can “accelerate” CVD risk in shorter duration type 1 diabetes to the 
equivalent of older, longer duration individuals.  Further examination of the risk factor profile of 
Group B showed that the mean non-HDLc was 165.5 (SD 37.7) and HbA1c was 9.5 (SD 1.8), 
both of which were the highest of all of the five groups identified by TSSA (Table 6).  These 
results provide considerable support for more intensive lipid and HbA1c control in short duration 
type 1 diabetes.  Finally, two high risk groups were identified: both had longer diabetes 
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duration/older age, but one mostly female, characterized by higher WBC, and smoking rates 
(Group D, CVD risk 81.5%) and the other mostly male, characterized primarily by renal disease 
(Group E, CVD risk 85.2%). 
That AER was the primary factor discriminating risk at longer, but not shorter, duration 
may be related to more severe albuminuria as diabetes duration increases.  The chosen AER cut-
point of approximately 92 µg/min falls within the microalbuminuria range (20-200 µg/min). 
However, further investigation (Table 6) of the group with AER >92 µg/min (Group E) showed 
that the majority had overt nephropathy (AER >200 µg/min), which is a well-established CVD 
risk factor in type 1 diabetes (83–86).  Within the lower AER group, WBC further discriminated 
total CVD risk, such that those with lower AER, but higher WBC (Group D, 82% CVD risk) 
were at nearly equivalent risk to those with higher AER (Group E, 85% CVD risk).  Further 
examination of Group D showed that it had the highest rate of smoking of the five groups 
identified by the TSSA analyses (Table 6), which may contribute to both high WBC levels and 
CVD rate of this group. 
When separate trees were fit by sex, AER only discriminated CVD risk in men.  This 
supports the earlier observation that renal disease may be a more important CVD risk factor in 
men compared to women (56).  Non-HDLc discriminated risk in men only if AER was lower. In 
women, diabetes duration was the major discriminating factor and non-HDLc further 
discriminated CVD risk in those with shorter diabetes duration.   
In the earlier, 1950-1964 diagnosis cohort, AER was the only discriminating factor 
identified, which concurs with the total CVD tree, where AER was important at longer diabetes 
duration.  In contrast, the 1965-1980 diagnosis cohort first split on non-HDLc and AER only 
discriminated risk at lower levels of non-HDLc. Interestingly, the lower-non-HDLc/higher AER 
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group had nearly the same CVD risk as the higher-non-HDLc/longer duration group (71 and 
74%, respectively).  The differences in the trees between the two diagnosis cohorts support the 
evidence that there may be a declining role of renal disease on CVD.  Rates of renal disease, 
particularly end-stage renal disease, have declined with time (168) and albuminuria has been 
shown to be less likely to precede CVD than previously reported (194).     
The tree for CVD mortality first split on AER at a cut-point of 26.9 µg/min.  This cut-
point is close to the cut-point used to define the lower limit of microalbuminuria (20-200 
µg/min), which is strongly associated with higher all-cause mortality (195,196) and CVD rates 
(84,86,197) in type 1 diabetes.  Diabetes duration modified risk at both levels of AER, such that 
having duration ≥23 years was associated with a 6-fold increase in risk within the lower AER 
group and having duration of ≥22 years was associated with an approximately 2.5-fold risk 
within the higher AER group. 
The tree for CAD was similar to the total CVD tree, which is not surprising as CAD was 
the most common manifestation CVD in this cohort.  The chosen optimal cut-points for the risk 
factors differed slightly than those chosen for total CVD, with the non HDLc cut-point in the 
CAD tree being 9 units lower than in the total CVD tree (123 and 132 mg/dl, respectively).  
Conversely, the AER cut-point was 40 units higher in the CAD compared to the total CVD tree 
(132 and 92 µg/min, respectively).     
For stroke, non-HDLc <115.6 mg/dl was associated with very low risk of <0.5% over 25 
years.   The combination of non-HDLc≥115.6 mg/dl and AER≥54.3 µg/min led to a moderate 
16% risk of stroke. Interestingly, having higher non-HDLc and WBC≥9.2x103/µl, but lower 
AER, led to the highest level of risk, at 25%.  This relationship between very elevated WBC and 
stroke merits further study.  WBC has been reported as a risk factor for stroke in the EDC study 
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(198), as well as in the general population (199–201), but a threshold effect at such a high WBC 
level on the long-term risk of stroke, has not been previously reported, to our knowledge.  
Generally, little is known about the predictors of stoke in type 1 diabetes, as there have been few 
reports.   Serum lipids have been associated with stroke incidence in the Fremantle (202) and 
EDC studies (198), but not in the WHO Multinational Study of Vascular Disease in Diabetes 
(WHO MSVDD) (203), while nephropathy was shown to be strongly associated with stroke in 
both the EDC and the MSVDD (198,203).  
Finally, the tree for LEAD split on diabetes duration and then, within both shorter and 
longer duration, split on non-HDLc at 132.5 mg/dl and 164.6 mg/dl, respectively.  The shorter 
duration/higher non-HDLc group had nearly the same risk of LEAD as the longer duration/lower 
non-HDLc group (28 and 32%, respectively), again underscoring the importance of lipid control 
in type 1 diabetes, especially with diabetes duration <25 years.  This relatively short duration 
corresponds to an average age of only 33 years in this cohort of childhood-onset type 1 diabetes.  
That non-HDLc was the major discriminating factor concurs with the results from an earlier 
analysis of the EDC study at 6 years of follow-up, which found that serum lipids predicted 
LEAD, but renal damage did not (58).  In the general population, serum lipids have also been 
strongly associated with the development of LEAD (204–210).   
Strengths and limitations 
The EDC cohort is a prospective study with 25 years of follow-up to ascertain CVD 
outcomes.  The cohort is well characterized, with data available for many clinical risk factors, 
and represents a wide range of diabetes diagnosis years.  CVD events were verified using death 
certificates and medical records by reviewers masked to risk factor status. One limitation of the 
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study is that the cohort is 98% Caucasian, due to the demographics of Allegheny County, 
Pennsylvania (<15% African American), and lower type 1 diabetes incidence among African 
Americans during the period when the cohort was diagnosed, so it is not known if these results 
apply to other groups.  There is also a potential for “survivor bias”, particularly in the older 
1950-1964 diagnosis subcohort, because prevalent cases of CVD were excluded from these 
analyses of incident events.  Only baseline risk factor data were included as predictors in these 
analyses, thus we cannot account for the impact of patterns of risk factor change over time.  
However, this situation is very appropriate for clinicians also have only a single data point 
available.  Finally, TSSA is considered to be an exploratory method and these results require 
external validation in other T1D cohorts before they can be applied in clinical settings.  In 
particular, TSSA is not easily amenable to the construction of models where inferential 
statements (using, e.g., p-values) can be made about the data. 
In conclusion, tree-structured survival analysis of the EDC study data suggests that 
subgroups with major CVD risk differences are identifiable by threshold effects of continuously 
measured risk factors. In many cases, similar levels of CVD risk are reached through different 
combinations of risk factor groupings. For total CVD, a high-risk group with shorter diabetes 
duration was identified which suggests that elevated non-HDLc increases CVD risk to the level 
of a longer diabetes duration group.  Within longer diabetes duration individuals, two high-risk 
groups were identified through distinct pathways:  one mostly female, with high rates of 
smoking, and WBC, and the other mostly male, characterized by renal disease. Utilizing decision 
tree methods to identify subgroups at higher levels of risk in this manner may help to shed light 
on the various pathways leading to CVD outcomes. Further study, including external validation, 
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is needed to better determine the prognostic utility of TSSA and the identification of subgroups 
at varying levels of CVD risk in type 1 diabetes. 
67 
4.0  HEMOGLOBIN A1C AND CARDIOVASCULAR DISEASE INCIDENCE IN 
TYPE 1 DIABETES:  AN APPLICATION OF JOINT MODELING OF LONGITUDINAL 
AND TIME-TO EVENT DATA IN THE PITTSBURGH EPIDEMIOLOGY OF 
DIABETES COMPLICATIONS (EDC) STUDY 
4.1 ABSTRACT 
The reasons for the increased risk of cardiovascular disease (CVD) in type 1 diabetes 
(T1D) are not fully understood. The hyperglycemia, measured by HbA1c, that characterizes T1D 
has been an inconsistent predictor of CVD incidence.  However, only baseline HbA1c or a 
summary measure, such as the mean over follow-up, is usually analyzed.  Joint modeling allows 
longitudinal repeated covariates, modeled using random effects, and the time-to-event data to be 
modeled together. Thus our objective was to assess the association between serially measured 
HbA1c and CVD incidence using joint modeling.  Data were from the Pittsburgh Epidemiology 
of Diabetes Complications (EDC) study, a prospective cohort study of childhood-onset T1D that 
has repeatedly reported little association between mean baseline or follow-up HbA1c and 
coronary artery disease incidence.  Of 561 participants without CVD at baseline, 263 (42.1%) 
developed CVD over 25-years. Each one unit increase in HbA1c was associated with a 1.4-fold 
increase in the risk of CVD (95% CI: 1.17, 1.72), after adjusting for baseline values of other 
CVD risk factors, and a 1.3-fold increased risk (95% CI: 1.03, 1.42) after adjusting for updated 
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means of other factors.  These findings, which support the need for good glycemic control to 
prevent CVD in T1D, underscore the importance of utilizing methods that incorporate within-
subject variation over time when analyzing and interpreting data from longitudinal cohort 
studies.      
4.2 INTRODUCTION 
Cardiovascular disease (CVD), comprising coronary artery disease (CAD), 
cerebrovascular disease, and peripheral vascular disease, is a major complication of type 1 
diabetes.  As in the general population, CVD is a significant contributor to morbidity and early 
mortality in individuals with type 1 diabetes, however the risk of CVD is greatly increased in 
type 1 diabetes (55).  The reasons for this increased risk are not fully understood, as the 
hyperglycemia, as measured by HbA1c, that characterizes type 1 diabetes is itself an inconsistent 
predictor of CVD incidence (56–64).  In the Diabetes Control and Complications Trial 
(DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) follow-up study, the 
intensive diabetes therapy arm had significantly lower incidence of CAD compared to the 
conventional therapy arm (211).  Also, in a more recent analysis, updated weighted-mean HbA1c 
was found to be an important predictor of CVD incidence, second only to age (187).  In contrast, 
observational studies have not found HbA1c to be a consistent predictor of CVD events 
(58,60,61,75,66,76,77).  One potential explanation for these seemingly discordant results is that, 
in the DCCT, intensive therapy was begun early in the course of diabetes, raising the suggestion 
that glycemia may play a role in the initiation of atherogenesis (78).  Despite the level of HbA1c 
not predicting CAD incidence, in the Pittsburgh Epidemiology of Diabetes Complications (EDC) 
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study, a prospective cohort study of childhood-onset type 1 diabetes, decreasing HbA1c over 
time was associated with a lower risk of CVD (62).  Additionally, HbA1c variability, but not 
mean HbA1c over time, was predictive of CVD events in the FinnDiane study (77).  In contrast 
to this inconsistent relationship between HbA1c and CAD, glycemia has been more consistently 
associated with an increased risk of peripheral artery disease (PAD) (58,79,80).  This difference 
may indicate that hyperglycemia is more strongly associated with stable atherosclerosis, which 
characterizes PAD, rather than plaque rupture, which precipitates the acute coronary events (78).  
Stable atherosclerosis is characterized by plaques with high fibrous and lower macrophage and 
lipid content and evenly distributed atherosclerosis around the circumference of the vessel lumen 
(212).  Unstable atherosclerosis is characterized by “vulnerable plaques”, which have a necrotic 
core highly prone to produce a thrombus, or clot, and are covered by thin, fibrous caps (212). In 
the general population, the majority of acute coronary events are precipitated by the rupture of 
vulnerable plaques, with only a small proportion resulting from erosion of more stable 
atherosclerotic plaques (81,82).  In type 1 diabetes, these proportions are reversed with the 
majority of events due to plaque erosion (81,82), consistent with the hypothesis that 
hyperglycemia is associated with more stable atherosclerosis. 
In the observational cohort studies used to examine these associations, baseline HbA1c is 
most often used as a predictor of CVD incidence. This approach, while generally providing valid 
results, does not account for changes in glycemic control over time that may affect risk 
(128).  For example, this approach may underestimate the effect of HbA1c if it becomes more 
important closer to the time of the event.  Stability and change of predictors are relevant for 
determining the likelihood of an individual having an event, thus incorporating within-subject 
patterns is important for obtaining a more complete understanding of the relationship between 
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risk factor and outcome (128–131). Analyses of data from longitudinal cohort studies rarely 
make full use of the information contained in serially measured risk factors and, in some cases, 
failing to utilize all available data may lead to invalid results (128). 
One common approach for accommodating change of risk factors in statistical analyses is 
to model change directly (132).  However, this approach does not account for the actual pattern 
of change and assumes a constant, linear increase or decrease over the follow-up and may also 
underestimate the variance of the factor (133).  Another approach for utilizing longitudinal data 
is to model the average (or updated mean) risk factor over the follow-up period. However, this 
method has similar drawbacks to modeling change, leading to a loss of important information 
regarding variability over time (134).   
 Joint modeling allows both longitudinal repeated covariates and time-to-event data 
to be modeled together, as detailed by Wulfsohn and Tsiatis (160).  Comprehensive 
overviews of joint models have also been provided by Tsiatis and Davidian (213) and by Diggle 
et al. (214). Briefly, a joint model consists of two submodels.  A mixed-effects model 
characterizes the trajectory over time of the longitudinal covariate.  The modeled random effects 
are simultaneously included in a survival model, so that the relationship between the pattern of 
covariate change and time to the event of interest can be estimated (131).  These random effects, 
or subject-specific deviations from the average effect, are assumed to be the underlying link 
between the longitudinal repeated measures and the subject-specific hazard for the time-to-event 
outcome (128). 
While survival analyses and repeated measures analyses using mixed models have 
separately been performed using EDC study data, jointly modeling both processes has not 
previously been carried out.  Thus, our objective is to assess the relationship between serially 
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measured HbA1c and the incidence of CVD using joint modeling.  Additionally, the specific 
manifestations of CVD (i.e. coronary artery disease, LEAD, CVD mortality, etc.) were examined 
separately to explore whether the relationship with HbA1c differs by type. 
4.3 METHODS 
4.3.1 Study Population 
The Pittsburgh EDC Study is a prospective cohort study of childhood-onset (<17 years 
old) T1DM. All participants (n=658) were diagnosed, or seen within one year of diagnosis, at 
Children’s Hospital of Pittsburgh between 1950 and 1980. The cohort has been described in 
detail elsewhere (167,168). In brief, participants have been followed since 1986-1988, initially 
with biennial examinations and questionnaires for ten years and thereafter with biennial 
questionnaires and further examinations at 18 and 25 years post-baseline. Research protocols 
were approved by the University of Pittsburgh institutional review board and all participants 
provided written informed consent.   
4.3.2 Ascertainment of Cardiovascular Outcomes 
Participants were followed for 25 years to assess the incidence of total CVD, defined as 
the first instance of CAD (fatal CAD, myocardial infarction, revascularization procedure, 
blockage ≥50%, ischemic ECG, or angina), stroke, or LEAD (Ankle brachial index (ABI) <0.8, 
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lower limb amputation due to vascular cause, or intermittent claudication).  Fatal events were 
ascertained using medical records, death certificates, autopsy reports, and/or interview with next 
of kin and classified according to the Diabetes Epidemiology Research International (DERI) 
system (169).  Myocardial infarction, revascularization/blockage, and stroke were self-reported 
by the study participants and confirmed by medical records.  Amputation was ascertained by 
self-report and/or physician examination.  ABI was determined using a Doppler blood-flow 
detector with the subject supine and ratios for each of the right and left tibialis posterior and 
dorsalis pedis systolic pressures were calculated with arm systolic pressure as the denominator. 
Intermittent claudication was assessed using the Rose questionnaire (192).   In addition to total 
CVD, the following alternative outcomes were assessed: total CAD, stroke, LEAD, and CVD 
mortality (CAD death, fatal MI, or fatal stroke).  Participants with prevalent CVD at baseline 
were excluded from analyses of the corresponding outcome. 
4.3.3 Risk Factor Assessment 
Risk factors were assessed at baseline and repeated at 2-, 4-, 6-, 8-, 10-, and 18-years of 
follow-up. Fasting blood samples were taken to measure HbA1/HbA1c, lipids, and serum 
creatinine.  From baseline through 10 years of follow-up, HbA1 values were converted to 
DCCT-aligned HbA1c values using a regression equation derived from duplicate assays (DCCT 
HbA1c=0.14 + 0.83[EDC HbA1]) (62).  At the 18-year examination, HbA1c was measured 
using the DCA 2000 analyzer (Bayer Healthcare LLC. Elkhart, IN) and converted to DCCT-
aligned HbA1c by the equation: DCCT HbA1c=(EDC HbA1c-1.13)/0.81.  From baseline 
through the 10-year examination, serum total cholesterol and triglycerides were determined 
enzymatically (170,171) and HDL cholesterol was determined using a modified precipitation 
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technique (172) based on the lipid research clinics method (173).  At the 18-year examination, 
serum lipids were measured using the Cholestech LDX (Cholestech Corp., Hayward, CA). Non-
HDL cholesterol (non-HDLc) was calculated by subtracting HDL cholesterol from total 
cholesterol.  White blood cell count (WBC) was determined using a Coulter Counter.  Three 
seated blood pressure readings were taken with a random-zero sphygmomanometer, and the 
mean of the second and third readings was used in analyses, according to the Hypertension 
Detection and Follow-Up protocol (175).  Hypertension was defined as blood pressure ≥140/90 
mmHg or use of blood pressure-lowering medication.  Past and current smoking status was 
obtained by self-report.  At study visits, three timed urine samples (24-hour, overnight, and 4-
hour collections obtained over a two week period) were collected.  Urinary albumin was 
measured in each sample by immunonephelometry (176) and albumin excretion rate (AER) was 
calculated; the natural log transformed median of the three AERs was used in analyses.  Serum 
creatinine was measured using an Ectachem 400 Analyzer (Eastman Kodak Co., Rochester, NY).  
Glomerular filtration rate (eGFR) was estimated by the Chronic Kidney Disease Epidemiology 
Collaboration (CKD-EPI) creatinine equation (193).  A positive renal disease status at baseline 
was defined as AER≥200µg/min in at least 2 of the 3 timed urine samples, eGFR<60 ml/min/m2, 
or a history of renal transplant or dialysis.  
4.3.4 Statistical Analyses 
Prevalent cases of CVD at baseline were excluded. Baseline characteristics were 
compared between those who developed CVD during the 25 years of follow-up and those who 
did not using two-sample t-tests for continuous variables (or Wilcoxon rank-sum, if data were 
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not normally distributed) or using chi-squared tests for dichotomous variables in SAS v. 9.3 
(SAS Institute, Cary, NC).  Longitudinal HbA1c and time to first CVD event were the outcomes 
of interest and were examined simultaneously using joint models (160,165).  For the longitudinal 
sub-model, a subject-specific random effects model with random intercept and slope was used to 
examine the trajectory of HbA1c over follow-up.  HbA1c was censored at the time point 
immediately prior to the CVD event for cases.  For the survival submodel we employed a Cox 
proportional hazards model.  Interactions between longitudinal HbA1c and important pre-defined 
subgroups, specifically diabetes diagnosis cohort (diabetes diagnosed 1950-64 versus 1965-80), 
sex, and renal disease at baseline, were tested to determine whether the longitudinal HbA1c 
trajectory differed by group. Models were repeated separately with time to CAD, stroke, and 
LEAD as the outcome, respectively.   All models were adjusted for other baseline CVD risk 
factors and final models were selected using backward selection and likelihood ratio tests. The 
risk factors considered for adjustment were years of diabetes duration, non-HDLc, hypertension, 
ln(AER), and white blood cell count, except in cases where collinearity was a concern (i.e. 
models including the diagnosis cohort indicator were not adjusted for diabetes duration and those 
including the renal disease status indicator were not adjusted for ln(AER)).  Alternate models 
were fit adjusting for the updated mean of each factor (i.e. the mean value of all available 
measurements prior to event or censoring), instead of baseline values.   All joint modeling was 
performed using the joineR routine in R (165,145).    
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4.4 RESULTS 
Of the 561 participants free of CVD at baseline, 263 (42.1%) went on to develop CVD 
during the 25-year follow-up.  Baseline characteristics by CVD incidence status are shown in 
Table 5.  The participants who developed CVD were significantly older, had longer diabetes 
duration, higher body mass index, waist-hip ratio, non-HDLc, triglycerides, blood pressures, 
white blood cell count, and AER and lower eGFR.  They were also more likely to be taking 
blood pressure lowering medication, have hypertension, and report past smoking.  The median 
follow-up time for CVD ascertainment was 15.0 years (range 0.2 to 27.7 years).  The survival 
curve for total CVD is shown in Figure 8 and the observed mean longitudinal HbA1c profile by 
CVD incidence status is shown in Figure 9.  
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Figure 7.  Kaplan Meier Curve for Survival Free of Cardiovascular Disease (CVD) Over 25 Years of Follow-
Up 
Figure 8. Observed Mean HbA1c by 25-Year Total Cardiovascular Disease Incidence Status 
Error bars are ±standard error 
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Three models were fit to associate HbA1c trajectories (longitudinal component) with 
time to total CVD (survival component): (1) a joint model where both the longitudinal and 
survival sub-models were not adjusted for other covariates, (2) a joint model where both the 
longitudinal and survival sub-models were adjusted for baseline covariates, and (3) a joint model 
where both the longitudinal and survival sub-models were adjusted for covariates averaged over 
the follow-up (Table 7).  In model 1, there was a statistically significant mean decrease in HbA1c 
of -0.03 units per year (95% CI: -0.05, -0.02).  For the corresponding survival sub-model, the 
association parameter was 0.43 and was statistically significant (95% CI: 0.26, 0.64), indicating 
that there is strong evidence of an association between the two sub-models. In other words, 
HbA1c is associated with CVD risk at any given time t.  In model 2, after adjusting for baseline 
diabetes duration, non-HDLc, hypertension, ln(AER), and WBC, the association parameter of 
0.33 was only slightly attenuated and remained statistically significant.  Thus, each one unit 
increase in HbA1c was associated with an exp(0.33)=1.4-fold increase in the risk of CVD (95% 
CI: 1.17, 1.72), after covariate adjustment.  In model 3, adjusted for diabetes duration and 
updated mean non-HDLc, ln(AER), and WBC, the association parameter was further attenuated, 
but remained significant at 0.22 (95% CI: 0.03, 0.35), corresponding to a 1.25-fold increased risk 
of CVD (95% CI: 1.03, 1.42) per unit increase in HbA1c. 
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Table 7. Estimated Coefficients and 95% Confidence Intervals From a Joint Model with a 
Random Effects Longitudinal HbA1c Sub-Model and a Cox Survival Sub-Model for Time 
to Total Cardiovascular Disease (CVD) 
Model Model 
Adjustment 
Sub-Model Covariates Estimate 95% CI 
1 Unadjusted, 
Main Effects 
Only 
Longitudinal 
HbA1c random 
effects 
Intercept 
Time 
9.03 
-0.03
8.90, 9.12 
-0.05, -0.02
Cox Survival Association Parameter 0.43 0.26, 0.64 
2 Adjusted for 
Baseline 
CVD Risk 
Factors 
Longitudinal 
HbA1c random 
effects 
Intercept 
Time 
Diabetes Duration 
Non-HDLc 
Hypertension 
8.29 
-0.035
-0.03
0.009
-0.36
7.58, 8.53 
-0.05, -0.02
-0.04, -0.01
0.008, 0.01
-0.70, -0.08
Cox Survival Diabetes Duration 
Non-HDLc  
Hypertension 
ln(Albumin Excretion 
Rate)  
White Blood Cell Count 
Association Parameter 
0.07 
0.008 
0.52 
0.15 
0.10 
0.33 
0.05, 0.09 
0.004, 0.01 
0.07, 0.99 
0.08, 0.21 
0.02, 0.18 
0.16, 0.54 
3 Adjusted for 
Updated 
Mean CVD 
Risk Factors 
Longitudinal 
HbA1c random 
effects 
Intercept 
Time 
Diabetes Duration 
Non-HDLc 
ln(Albumin Excretion 
Rate) 
7.98 
-0.02
-0.03
0.01
0.11
7.47, 8.37 
-0.04, -0.01
-0.05, -0.02
0.006, 0.01
0.05, 0.15
Cox Survival Diabetes Duration 
Non-HDLc 
ln(Albumin Excretion 
Rate) 
White Blood Cell Count 
Association Parameter 
0.08 
0.01 
0.23 
0.10 
0.22 
0.08, 0.01 
0.005, 0.02 
0.17, 0.31 
0.03, 0.16 
0.03, 0.35 
There was a significant interaction between diabetes diagnosis cohort and time with 
respect to HbA1c trajectory (ß=-0.04, 95% CI: -0.08, -0.01).  The observed longitudinal 
trajectories of HbA1c by diabetes diagnosis cohort are depicted in Figure 10.  As seen in the 
graph, HbA1c was generally lower in the earlier 1950-1964 diagnosis cohort throughout follow-
up and this earlier cohort also experienced a more dramatic decline in HbA1c after 6 years of 
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follow-up compared to the more recent 1965-1980 diagnosis cohort.  Despite this interaction 
between diagnosis cohort and time with respect to HbA1c, the association between HbA1c 
trajectory and CVD risk was similar in both diagnosis cohorts (1950-1964, HR per 1-unit 
increase in HbA1c=1.30, 95% CI: 1.05, 1.65; 1965-1980, HR per 1-unit increase in 
HbA1c=1.21, 95% CI: 1.001, 1.46).  There were no significant interactions between sex or renal 
disease status at baseline and time with respect to HbA1c. 
Figure 9. Observed Mean HbA1c by Type 1 Diabetes Diagnosis Cohort 
Error bars are ±standard error     
The results of joint models for longitudinal HbA1c and the incidence of each specific 
manifestation of CVD adjusted for baseline CVD risk factors are shown in Table 8.   The 
longitudinal trajectory of HbA1c was significantly associated with each of the manifestations of 
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CVD, with a one unit increase in HbA1c associated with a 1.4-fold increased risk of both CAD 
and LEAD (95% CI: 1.05, 1.67 and 1.22, 1.67, respectively) and a 2-fold increased risk of stroke 
(95% CI: 1.5, 2.5).  Adjusting for updated mean CVD risk factors only slightly attenuated these 
associations and the longitudinal trajectory of HbA1c remained significantly associated with 
each CVD manifestation (Table 9).  In these alternate models, a one unit increase in HbA1c was 
associated with a 1.2-fold increased risk of CAD (95% CI: 1.03, 1.35), a 1.9-fold increased risk 
of stroke (95% CI: 1.26, 2.36), and a 1.3-fold increased risk of LEAD (95% CI: 1.11, 1.57).       
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Table 8. Estimated Coefficients from Joint Models with a Random Effects Longitudinal 
HbA1c Sub-Model and a Cox Survival Sub-Model for Time to Each Specific Manifestation 
of Cardiovascular Disease, Adjusted for Baseline Covariates 
Outcome Sub-Model Covariates Estimate 95% CI 
Coronary 
Artery Disease 
Longitudinal 
HbA1c random 
effects 
Intercept 
Time 
Diabetes Duration 
NonHDLc 
Hypertension 
ln(Albumin Excretion 
Rate)  
8.26 
-0.04
-0.03
0.008
-0.48
0.07
7.88, 8.60 
-0.05, -0.03
-0.04, -0.02
0.006, 0.01
-0.81, -0.17
0.01, 0.11
Cox Survival Diabetes Duration 
NonHDLc  
Hypertension 
ln(Albumin Excretion 
Rate)  
Association Parameter 
0.09 
0.008 
0.47 
0.15 
0.32 
0.07, 0.11 
0.004, 0.01 
0.03, 0.83 
0.06, 0.23 
0.05, 0.51 
Stroke Longitudinal 
HbA1c random 
effects 
Intercept 
Time 
Diabetes Duration 
NonHDLc 
Hypertension 
8.33 
-0.04
-0.02
0.009
-0.36
7.81, 8.62 
-0.05, -0.03
-0.03, -0.01
0.007, 0.01
-0.66, -0.07
Cox Survival Diabetes Duration 
NonHDLc  
ln(Albumin Excretion 
Rate)  
Association Parameter 
0.08
0.01
0.27
0.71
0.03, 0.11
0.008, 0.02
0.15, 0.39
0.40, 0.92
Lower 
Extremity 
Arterial 
Disease 
Longitudinal 
HbA1c random 
effects 
Intercept 
Time 
Diabetes Duration 
NonHDLc 
8.39 
-0.03
-0.03
0.009
7.96, 8.71 
-0.05, -0.02
-0.05, -0.02
0.007, 0.012
Cox Survival Diabetes Duration 
NonHDLc 
Association Parameter 
0.06 
0.01 
0.34 
0.04, 0.09 
0.008, 0.02 
0.20, 0.51 
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Table 9.  Estimated Coefficients from Joint Models with a Random Effects Longitudinal 
HbA1c Sub-Model and a Cox Survival Sub-Model for Time to Each Specific Manifestation 
of Cardiovascular Disease, Adjusted for Updated Mean Covariates 
Outcome Sub-Model Covariates Estimate 95% CI 
Coronary 
Artery Disease 
Longitudinal 
HbA1c random 
effects 
Intercept 
Time 
Diabetes Duration 
NonHDLc 
ln(Albumin Excretion 
Rate)  
7.92 
-0.03
-0.03
0.0009
0.11 
7.30, 8.33 
-0.05, -0.02
-0.05, -0.02
0.007, 0.013
0.04, 0.17 
Cox Survival Diabetes Duration 
NonHDLc  
ln(Albumin Excretion 
Rate)  
White Blood Cell Count 
Association Parameter 
0.10 
0.008 
0.24 
0.10 
0.18 
0.08, 0.12 
0.004, 0.01 
0.13, 0.31 
0.0009, 0.18 
0.03, 0.30 
Stroke Longitudinal 
HbA1c random 
effects 
Intercept 
Time 
Diabetes Duration 
NonHDLc 
ln(Albumin Excretion 
Rate) 
8.04 
-0.04
-0.03
0.009
0.11
7.71, 8.41 
-0.05, -0.03
-0.05, -0.02
0.006, 0.011
0.06, 0.16 
Cox Survival Diabetes Duration 
NonHDLc  
ln(Albumin Excretion 
Rate)  
Association Parameter 
0.07 
0.013 
0.44 
0.62 
0.04, 0.11 
0.004, 0.02 
0.28, 0.59 
0.23, 0.86 
Lower 
Extremity 
Arterial 
Disease 
Longitudinal 
HbA1c random 
effects 
Intercept 
Time 
Diabetes Duration 
NonHDLc 
ln(Albumin Excretion 
Rate) 
8.08 
-0.03
-0.04
0.009
0.11
7.61, 8.46 
-0.05, -0.02
-0.05, -0.02
0.006, 0.011
0.06, 0.15 
Cox Survival Diabetes Duration 
NonHDLc 
ln(Albumin Excretion 
Rate) 
Association Parameter 
0.06 
0.014 
0.17 
0.30 
0.04, 0.08 
0.008, 0.018 
0.06, 0.27 
0.10, 0.45 
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4.5 DISCUSSION 
Our findings show that the longitudinal trajectory of HbA1c is associated with 25-year 
CVD incidence in this cohort of long-standing childhood onset type 1 diabetes and that this 
association does not differ by the specific manifestation of CVD.  The results of these joint 
models show that CVD risk is associated with the combination of a subject’s level of Hba1c at 
baseline and rate of change of HbA1c over follow-up, a longitudinal process represented by a 
random intercept and slope.  A one unit increase in the level of HbA1c is associated with a 40% 
increased risk of developing CVD, after adjusting for baseline CVD risk factors, and a 25% 
increased risk of CVD, after adjusting for each participant’s mean values of CVD risk factors 
over the follow-up.      
These results provide additional insight into the role of HbA1c on CVD risk, compared to 
other methods of assessing this relationship, such as modeling baseline HbA1c (62,215), updated 
mean HbA1c, change between the first and last HbA1c measurements (62), or a cumulative 
measure of glycemic exposure (58) as predictors.   Prior analyses of EDC data using baseline 
HbA1c, were unable to demonstrate an association between glycemia and CAD incidence 
(58,215). As evident in the plots of HbA1c trajectories shown in Figure 2, the level of HbA1c at 
baseline did not differ in those participants who went on to develop CVD versus those who did 
not.  However, as time progressed, the HbA1c trajectories between the two groups grew farther 
apart. Interestingly, in both groups, mean HbA1c rose until 6 years of follow-up, albeit more so 
in the CVD cases, which corresponds to calendar years 1992-1994, and began to decline steadily 
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thereafter, likely reflecting the implementation of intensive insulin therapy into clinical practice 
following the results of the DCCT (216).  In another prior EDC analysis, based on a 16 year 
follow-up, absolute change in HbA1c was significantly associated with CAD risk (62).  In those 
analyses, CAD cases had a mean increase in HbA1c of +0.62 between their first and last 
measures, while noncases had a mean decrease of -0.09.  The current analyses add additional 
information by incorporating all available HbA1c measures and within subject-variability, 
allowing us to quantify the increase in CVD risk associated with each unit increase in HbA1, 
while also adjusting for the mean level of other risk factors over time.  
Attenuation of the association between longitudinal HbA1c and CVD was somewhat 
greater when adjusting for the updated means of other CVD risk factors, compared to adjusting 
for the baseline values.  Additional analyses to determine which factors lead to the attenuation of 
the HbA1c effect revealed that mean non-HDLc had the greatest impact (data not shown).  Non-
HDLc is traditionally an important CVD risk factor in general, regardless of diabetes status and 
individuals with type 1 diabetes typically do not have higher non-HDLc levels than observed in 
the general population.  A report using data from the National Health and Nutrition Examination 
Surveys estimated that US adults had a mean non-HDLc of 155 mg/dl (95% CI 153-157) 
between 1988-1994 (217).  This value is markedly higher than the mean non-HDLc observed in 
the EDC cohort both at the 1986-1988 baseline (Table 5) and over follow-up (mean over all 
cycles=136.3, SD=36.3), thus non-HDLc level itself does not seem to explain the increased CVD 
risk associated with type 1 diabetes in this cohort. It is, however, possible that the effect of non-
HDLc could be modified by diabetes, so that CVD risk is increased even at lower levels of non-
HDLc.   Even given the observed attenuation of the effect of the HbA1c trajectory on CVD risk, 
the HbA1c trajectory remained a significant predictor of CVD independent of non-HDLc, 
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demonstrating that glycemic control may explain more of the increased CVD risk than has 
previously been shown in observational studies.  These findings are consistent with the recent 
report from the DCCT/EDIC, where updated weighted-mean HbA1c was found to be an 
important predictor of CVD incidence independent of lipid levels (187). 
 From a clinical perspective, these results provoke questions as to how the 
relationship observed here can be used to determine which patients should be targeted for CVD 
prevention based on their level of glycemic control. Data from a longitudinal study can be used 
to examine etiologic pathways that may take many years of follow-up to be revealed.  This 
information is in contrast to clinically available information, where often only a current snapshot 
of risk factor level is accessible. Potentially, this type of joint modeling could be used to create a 
“2-step” prediction model.  For example, cross-sectional HbA1c and other clinical characteristics 
are entered to first predict the longitudinal trajectory of HbA1c over time and then to 
subsequently translate this predicted trajectory into a patient’s risk of developing CVD.  An 
important unanswered question is whether some individuals are resistant to the benefits of 
intensive insulin therapy and would continue to be at high risk for CVD, regardless of HbA1c 
control.  As shown in Figure 9, in the EDC, the pattern of glycemic control was generally worse 
over time in those who developed CVD compared to those who did not. However, it is unclear 
whether hyperglycemia in the CVD cases was undertreated or if this group is resistant to the 
benefits of appropriate treatment.  The mean insulin dose between the CVD cases and noncases 
did not differ at baseline (Table 5) or at any other point during the follow-up (data not shown), 
suggesting that equivalent treatment for glycemia was less effective in those who went on to 
develop CVD.   It is possible that there are genetic factors that drive both resistance to glycemic 
control and CVD risk.  Identifying such factors is an important area of future research.        
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Our study has many strengths.  The EDC is a well-characterized, prospective cohort 
study with 25 years of follow-up to ascertain CVD incidence and clinical risk factors.  CVD 
events were verified using death certificates and medical records by reviewers who were masked 
to risk factor status.  Only HbA1c measurements prior to CVD incidence were included in these 
analyses to minimize the potential for reverse causality.  Using joint modeling we were able to 
incorporate all HbA1c measurements and model the longitudinal trajectory taking the within-
subject variability into account.  The major advantage of joint modeling is that it allows the 
relationship between longitudinal repeated measures and a time-to-event outcome to be 
examined.  As emphasized by Lim et al., joint modeling may be particularly useful when the 
goal is to use longitudinal measures of biomarkers to improve prediction of an event (128).  
Another advantage of using joint modeling in this type of application is that it is able to reduce 
the potential for bias associated with event-free survival far beyond the last measurement of a 
longitudinal covariate by accounting for the subject-specific random effects (131). Using simpler 
methods, such as modeling the two processes separately, may lead to bias if some subjects 
survive far beyond the most recent follow-up.  Joint modeling is able to account for this 
differential follow-up time by including the subject-specific random effects within the survival 
model (128,166).    
One limitation of our study is that the cohort is 98% Caucasian.  There are two main 
reasons for this overrepresentation of Caucasians: 1) the population of Allegheny County, 
Pennsylvania is <15% African American and 2) the incidence of type 1 diabetes was lower 
among African Americans during the period when the cohort was diagnosed. Consequently, it is 
unknown whether these results apply to more diverse groups.  There is also a potential for 
“survivor bias”, particularly in the older 1950-1964 diagnosis subcohort, because prevalent cases 
87 
of CVD at baseline were excluded from these analyses.  A limitation associated with joint 
modeling is that the censoring process is assumed to be independent of the random effects. If this 
assumption is violated then the parameter estimates may be biased (160).    
In conclusion, using joint modeling, we demonstrate that the longitudinal trajectory of 
HbA1c is associated with 25-year CVD incidence in this cohort of long-standing childhood onset 
type 1 diabetes and that this association does not differ by the specific manifestation of CVD.  
These results are in contrast to previous analyses using only baseline or mean HbA1c as 
predictors, which have not revealed a strong relationship between glycemic control and CVD 
(62,215).  Thus, these findings underscore the importance of utilizing methods that incorporate 
within-subject variation when analyzing data from longitudinal cohort studies.      
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5.0  DISCUSSION 
5.1 SUMMARY AND CONCLUSIONS 
These findings reflect a comprehensive examination of the epidemiology of CVD and its 
risk factors in type 1 diabetes.  Our first objective was to quantify the contemporary incidence 
and excess risk of CVD in young adults <45 years old with type 1 diabetes, which addresses a 
critical gap in the knowledge of this population in the United States.  We demonstrate that CVD 
risk continues to be significantly increased in type 1 diabetes, compared to the background 
population, and that this risk is particularly elevated in women with type 1 diabetes.  Our second 
objective was to utilize novel statistical methods to address limitations in the analyses of 
longitudinal cohort studies, in an effort to better understand the risk factor patterns that lead to 
the increased risk of CVD in this population.  One limitation of traditional analyses is that 
associations between risk factors and outcomes are assumed to be linear and continuous, 
ignoring the possibility of threshold effects or higher-order interactions between factors.  Using 
tree-structured survival analysis, we performed formal subgroup analysis and identified distinct 
groups at varying levels of risk for CVD, based on threshold effects of continuous risk factors.  
The factors defining these groups differed by diabetes diagnosis cohort and by sex, suggesting 
that the relative importance of CVD risk factors have changed over time and are different in men 
and women.  Another limitation in the analysis of cohort studies is the failure to adequately 
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utilize the repeated measures risk factor data by using only baseline or composite measures of 
risk factors that underestimate variability over time.  We used joint models to simultaneously 
model the longitudinal trajectory of HbA1c, including all measures obtained during the EDC 
follow-up, and time to CVD incidence.  We found that the longitudinal trajectory of glycemic 
control is associated with the risk of CVD.  Importantly, longitudinal HbA1c was similarly 
associated with all manifestations of CVD, including coronary artery disease, which is a new 
finding in this cohort.  Interestingly, longitudinal HbA1c was nearly equivalently associated with 
both CAD and LEAD, while the association was stronger for stroke incidence. These results 
support the findings from trial data, which show that glycemic control is important for 
preventing and delaying CVD, in addition to microvascular complications. 
5.2 FINDINGS 
5.2.1 Contemporary Cardiovascular Disease Burden 
A major gap exists regarding the contemporary burden of CVD in type 1 diabetes in the 
United States.  This is particularly true for young adults, who would be expected to have higher 
excess risk than older ages due to very low rates of CVD in young adults the general population.  
Additionally, treatment guidelines are unclear for young adults <40 years old, thus it is important 
to quantify risk in this group to inform clinical practice recommendations.  Treatment guidelines 
are based on extrapolations of data from the general and type 2 diabetes populations, but the 
usefulness of these recommendations in individuals with long duration type 1 diabetes is 
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questionable (185).  At any given age, the average duration of type 1 diabetes is significantly 
longer than type 2 diabetes, due to the typically younger age at onset.   
By examining data from EDC participants <45 years old between 1996-2012, we have 
attempted to address the question of whether there remains an excess risk of CVD, as was last 
demonstrated in the 1980s (55,69).  We found that both CVD mortality and hospitalized CVD 
event rates are still significantly increased compared to the age-matched background population.  
This increase is especially large for women, an issue discussed in further detail below. 
The excess CVD risk is consistent with data from other recent reports from Scotland (51), 
Sweden (52), and Australia (53), however, in our US cohort, our estimates suggest a greater 
excess risk than shown in all of these countries.  Differences in diabetes duration (i.e. length of 
exposure to diabetes) may explain some of the higher risk seen in the EDC cohort.  The other 
registries include adult-onset cases of type 1 diabetes, thus there is a shorter average diabetes 
duration at any given age.  There is also the distressing prospect that individuals with type 1 
diabetes in the United States are inadequately treated compared to their counterparts in other 
developed nations.  There is historical evidence to support this possibility.  A 1991 report from 
the DERI study found that premature mortality in type 1 diabetes was greater in the US and 
Japan compared to Finland and Israel (169).  Another prior report comparing data across 
countries showed that the United States has greater excess mortality associated with type 1 
diabetes than most of the European countries (with the exception of eastern Europe) and Canada 
(218).  The current findings add more evidence that prevention trials specific to type 1 diabetes 
are needed to address CVD risk in this high-risk population. 
We also quantified the absolute risk of CVD in young adults to address the question of 
whether their CVD risk is high enough to warrant statin therapy, regardless of cholesterol levels.  
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The American College of Cardiology/American Heart Association guidelines state that high-
intensity statin therapy is recommended in individuals between ages 40-75 years with diabetes 
and a ≥7.5% 10-year risk of CVD, but in individuals with diabetes who are <40 years old, the 
decision to being statin therapy should be individualized (73).  In cases of childhood-onset type 1 
diabetes, the duration of diabetes already exceeds 20 years by time an individual reaches age 30, 
so it is unclear how this recommendation should be applied in clinical practice.  In the EDC 
cohort, we find that young adults 30-39 years old have a 6.3% 10-year CVD risk, which 
approaches the 7.5% 10-year risk specified by the ACC/AHA guidelines.  However, it is 
important to note that 5% of this age group in the EDC cohort was already on lipid-lowering 
medication in 1996 and this proportion rose to 20% by 2012.  Thus, we can reasonably assume 
that the 10-year risk would exceed 7.5% if none of the cohort were using lipid-lowering 
medication.  These results support recommending statin therapy to all individuals with type 1 
diabetes duration of >20 years who are at least 30 years old and underscore the need for trial data 
specific to type 1 diabetes.          
5.2.2 Cardiovascular Disease Risk Stratification and Interactions Between Risk Factors 
The excess CVD risk that persists in type 1 diabetes also points to the need for better 
identification of individuals who are at high risk for targeted interventions.  Recommending 
statin therapy to a wider group, as discussed above, is an important strategy to consider. It is also 
likely that assessing the possibility of interactions between multiple risk factors could lead to the 
identification of subgroups, which may benefit from interventions that target a range of risk 
factors.  Using tree-structured survival analysis (TSSA), we were able to demonstrate the 
presence of such meaningful subgroups with differing levels of CVD risk in the EDC cohort.  
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For total CVD, five groups were identified based on threshold effects of continuously measured 
risk factors.  Interestingly, the five groups were based on combinations of different risk factors, 
but corresponded to 3 levels of CVD risk:  a low risk (24%) group characterized by shorter 
diabetes duration and younger age, with a relatively good risk factor profile, two moderate risk 
groups, one with shorter diabetes duration and younger age, but high non-HDLc and HbA1c, and 
the other with longer diabetes duration and older age, but a good risk factor profile (50 and 53% 
risk, respectively), and two high risk groups, one mostly women with higher WBC and smoking, 
and the other mostly men with renal disease (82 and 85% risk, respectively).  There are several 
intriguing observations that can be made regarding these results.  One observation is that the risk 
factors profiles of the subgroups differed in ways additional to those characterized by the factors 
chosen by this computational method as the splitting factors.  In other words, the method 
discriminated subgroups that were distinct from each other in more ways than just the 
combinations of diabetes duration, non-HDLc, albumin excretion rate, and WBC that defined the 
groups.  Another important observation is that having high non-HDLc cholesterol seems to erase 
the protection against CVD associated with shorter diabetes duration/younger age.  This finding, 
in combination with our finding that CVD risk remains significantly elevated in young adults 
with type 1 diabetes, underscores the importance of more aggressive treatment of cholesterol 
beginning at younger ages in this population. The American Association of Clinical 
Endocrinologists guidelines state that non-HDLc should be below 130 mg/dl for people with 
diabetes and below 100 mg/dl in the cases of diabetes with another major risk factor (e.g. 
advanced age, smoking, family history of CAD) (219).  Here, the optimal cut-point for non-
HDLc in EDC participants with diabetes duration of <20 years was 132.5 mg/dl, which is close 
to the recommendation of 130 mg/dl.  Prior analyses from the EDC study examining various 
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LDLc target levels concluded that LDLc>100mg/dl was associated with an increased risk of 
CAD (220).  Generally, a non-HDLc cut-point of 30 mg/dl higher than the LDLc cut-point is 
recommended (221), so again, the 132.5 mg/dl identified here is consistent with these prior 
results. 
In this TSSA analysis, we used baseline factors, so they account for exposures at only a 
single time point, which excludes any interpretation regarding cumulative exposures or changes 
in risk factor patterns over time.  However, it is an important finding that baseline factors were 
able to discriminate between groups so well because this situation is similar to what is 
encountered in clinical practice, where a care provider may only have access to the most recent 
measurements.  Computational decision tree methods, like TSSA, hold promise for helping to 
better elucidating the interrelationships between risk factors to increase understanding of the 
pathophysiology of CVD.  Traditional regression-based analysis methods tend to examine 
whether risk factors are related to outcomes independently, but this approach ignores the 
complex interactions between risk factors that are certainly occurring (115,146).  As more 
computational tools become available, it will be important to utilize them to continue to increase 
our understanding of disease processes.     
5.2.3 Longitudinal Trajectory of Glycemic Control and Cardiovascular Disease 
The inconsistent relationship between glycemic control and cardiovascular outcomes has 
been a perplexing issue in type 1 diabetes research. As diabetes is characterized by 
hyperglycemia, it is natural to assume that glycemia should explain the excess CVD risk 
observed in type 1 diabetes.  In the DCCT/EDIC, the intensive insulin therapy arm had 
significantly lower CVD incidence than the conventional therapy arm (74), which leads to the 
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logical assumption that lower HbA1c is protective against CVD incidence.  However, this 
relationship has not been consistent across observational studies of type 1 diabetes (56–63).  One 
potential explanation for the discordant results is that the DCCT participants had a shorter 
diabetes duration at baseline, so the intensive insulin therapy was begun early in the course of 
disease, raising the possibility that glycemia plays a greater role in the initiation of atherogenesis 
than in its progression (78).  Another possibility is that the DCCT intensive insulin therapy arm, 
with a mean baseline HbA1c of 9.1%, achieved an average HbA1c of 7.4% after 6 years (74), 
which is significantly lower than the average HbA1c in the observational studies.  For example, 
in the EDC data shown here, mean HbA1c was 8.75% at the 1986-88 baseline, decreased to 
8.4% 10-years later, and was approximately 8.0% at 18 years of follow-up (Figure 9).  This 
difference between the DCCT and observational studies suggests that perhaps the benefit of 
glycemic control on CVD risk may only be achieved at very low levels of HbA1c.  Another 
major difference is that the observational studies have generally examined only baseline HbA1c 
as a predictor of CVD incidence.  This approach provides valid results but does not account for 
changes in glycemic control over time that may affect risk (128).  The DCCT results encompass 
six years of intensive insulin therapy, so cumulative improvement in glycemic control over the 
course of the trial is accounted for, even if it is not directly modeled.  Prior analyses of the EDC 
cohort have attempted to account for the cumulative effect of HbA1c by modeling HbA1c-
months, a measure of exposure to excess HbA1c, similar to pack-years of smoking (58,222).  
This cumulative measure was still not independently associated with coronary artery disease.  
Another, more recent, analysis of EDC data also confirmed no association between CAD and 
baseline or mean HbA1c over follow-up, but did detect an inverse relationship with absolute 
change in HbA1c (62).  These results suggest that analyses need to incorporate variability in 
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HbA1c over time, but still do not provide an estimate of the relative risk of CVD associated with 
the level of glycemic control at any given time.  This point is essential for clinical relevance, as 
healthcare providers may only have a patient’s current HbA1c measure.  
To address the limitations discussed above, here we have presented the results of joint 
models of the longitudinal trajectory of HbA1c and time to CVD event.  Joint models incorporate 
the subject-specific random effects into the time-to-event framework, and thus model the 
combined effect of a subject’s baseline HbA1c level and rate of change over follow-up on the 
risk of an outcome by utilizing a random intercept and slope.  This method allows us to quantify 
the relative CVD risk associated with each unit increase in HbA1c, averaged over the entire 
longitudinal trajectory.   We find that a one unit increase in the level of HbA1c is significantly 
associated with a 40% increased risk of developing CVD, after adjusting for baseline CVD risk 
factors, and a 25% increased risk of CVD, after adjusting for the mean values of CVD risk 
factors over follow-up.  CAD has been the specific CVD outcome with the most inconsistent 
relationship with HbA1c, but here a one unit increase in HbA1c is associated with a 40% 
increased risk of CAD, after adjusting for baseline factors, and a 20% increased risk of CAD 
after adjusting for mean risk factor values over follow-up.   
Graphically examining the longitudinal trajectories of HbA1c by CVD incidence status 
provides further insight into the lack of association that has been previously reported.  As seen in 
Figure 9, baseline HbA1c was nearly identical regardless of subsequent CVD incidence status.  
With little variability in HbA1c, an association between baseline HbA1c and CVD risk could not 
possibly be detected.  Significant separation in the two trajectories is not observed until 6 years 
of follow up.  These first several years of HbA1c measures would drive much of the mean 
HbA1c over time. After the first 6 years of follow-up, HbA1c began to steadily decline, 
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reflecting the implementation of the DCCT results into clinical practice.  Even though the rate of 
decline (i.e. the slope) after 6 years appears to be the same in subsequent CVD cases compared 
to noncases, the cases had a larger increase in the first 6 years, and their HbA1c was 
approximately 0.5 units higher than those who did not develop CVD over the remainder of 
follow-up. 
It is intriguing that baseline levels of other CVD risk factors, specifically lipids and blood 
pressure, are able to predict CVD incidence, while baseline HbA1c does not.  Examining the 
longitudinal trajectories of non-HDLc and systolic (SBP) and diastolic blood pressures (DBP) in 
EDC reveals that participants who go on to develop CVD have higher levels of these traditional 
risk factors throughout the entire follow-up, including the baseline examination.  The levels of 
non-HDLc, SBP, and DBP increase over time to a greater degree in the subsequent CVD cases, 
but there is still obvious separation between the cases and noncases even >20 years prior to the 
event or censoring time.  This observation suggests that lipid and blood pressure disturbances in 
patients at high risk for CVD may become apparent earlier in the natural history of diabetes.  In 
contrast, HbA1c levels were nearly equivalent at baseline and separation between cases and 
noncases became greater closer to the time of CVD event.  The reasons for this lack of variability 
in HbA1c at baseline are unclear.  Given the wide range of years of diabetes duration (6-36 
years) represented at the EDC baseline, it would be expected that glycemic control would also 
vary widely.  One possibility is that while the standard insulin regimen at the time of the EDC 
baseline examination was generally inadequate, some individuals were more susceptible to the 
effects of this inadequate regimen than others and their control worsened over time, leading to 
increased vascular risk.  This explanation is supported by the HbA1c trajectories shown in Figure 
9, where the participants who subsequently developed CVD had accelerated worsening of 
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HbA1c under the period of conventional treatment (i.e. through year 6).  Beginning in follow-up 
year 8, after intensive insulin therapy had been initiated in clinical practice, their HbA1c declined 
at a rate similar to those who did not develop CVD.   The traditional CVD risk factors may be 
more strongly related to lifestyle and genetic factors that are not specific to diabetes, and thus 
appear earlier in the lifespan.  The differences in the trajectories of HbA1c and the traditional 
CVD risk factors warrants further investigation. Though baseline values of these other traditional 
factors have consistently been shown to be associated with CVD incidence in type 1 diabetes, 
using utilizing joint models to examine the relationship between their longitudinal trajectories 
and CVD incidence should provide more precise estimates of relative risk.  This type of analysis 
may also reveal important differences in longitudinal trajectories between subgroups of 
participants (e.g. men and women).  Performing joint models analysis for other CVD risk factors 
using EDC data is an important area of future research. 
5.2.4 Cardiovascular Disease Risk and Risk Factors in Men and Women 
While in the general population, women have lower risk of CVD than men, in diabetes 
this protection is essentially erased and women are consistently shown to have nearly equivalent 
absolute CVD risk as men (56,68).  This lack of protection in diabetes also means that women 
with diabetes have a greater excess risk of CVD than men, an effect that has been consistently 
shown across international studies (50–53,183).  In a 2015 meta-analysis, Huxley et al. reported 
a pooled SMR for CVD mortality of 11.3 in women versus 5.7 in men (50).  The difference in 
excess risk was somewhat greater for CAD events, with a pooled incidence ratio of 13.3 in 
women and 5.6 in men.  The results presented here are consistent, also showing a greater excess 
risk in women of both CVD mortality (Table 2) and all definitions of CVD and CAD events 
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(Table 4).  The excess risk observed in EDC is even greater than seen in women of comparable 
ages in other recent reports; some potential reasons for this difference were discussed in section 
5.2.1.  However, this differential excess risk seen in EDC compared to the Scottish and Swedish 
registries is even greater in women than in men.  This difference is not likely to be explained by 
the longer average diabetes duration in EDC versus the registries, which should not differ 
significantly by sex.  Rather, the difference in excess risk by sex supports the hypothesis that 
there is a treatment bias unfavorable to women.  A cross-sectional analysis of data from the 
DCCT/EDIC showed that women were less likely than men to achieve an HbA1c of <7% or 
<8% (223).  Women were also less likely to be treated with statins even if they had elevated 
LDL cholesterol levels (223). Differences in treatment by sex have also been shown in type 2 
diabetes, where women have been shown to be less likely to be using statins (224,225) and 
aspirin therapy (226,227) and also less likely to achieve target blood pressure and lipid levels 
than men (225,227).  In the EDC, throughout the 1996-2012 follow-up in the young adults 
<45 years old examined here, women were about half as likely as men to report taking lipid-
lowering medications, despite similar levels of LDL cholesterol.  This difference in lipid 
medication use by sex was not statistically significant.  Nevertheless, our results suggest the 
possibility that these treatment differences by sex in type 1 diabetes may be greater in the United 
States, compared to other developed countries, and warrants further study. 
 Despite the similar rates of CVD incidence in men and women with type 1 
diabetes, there is evidence that the risk factors for CVD differ by sex (56).  In the EDC study, 
nephropathy was found to be a stronger risk factor for CAD in men than in women (56), 
although in the Eurodiab study nephropathy predicted CAD incidence in both sexes (61).  In the 
EDC, smoking is a stronger risk factor in men, perhaps due to the fact that men are more likely 
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to smoke or smoke more than women, while depressive symptomatology and physical activity 
appear to predict CAD more strongly in women (56).  Hyperglycemia has also been shown to 
contribute to the development of hypertension more strongly in men than women in EDC (228).  
Different distributions of lipid levels by sex can lead to differential relationships with CVD 
outcomes and may at least partially explain the excess risk seen in women.  For example, while 
HDL cholesterol is generally protective, very high HDL cholesterol (>80mg/dl) appears to 
increase CAD risk in women with type 1 diabetes (229).  In men, an inverse linear association is 
present in men, but very few have HDL cholesterol levels >80mg/dl.  
  Here we have also shown that factors for risk stratification differ in men and women.  
While sex was not chosen as a splitting factor, in the overall CVD decision tree (Figure 4), one 
of the major differences between the two high risk, long diabetes duration groups (Groups D and 
E) was a differential sex distribution.  Group D was mostly female and characterized by worse
glycemic control and a much higher rate of current smoking than Group E.  In contrast, Group E 
was mostly male with greater renal damage, as measured by their very high median AER, and 
lower mean estimated glomerular filtration rate.  When separate trees were fit by sex (Figure 6, 
Panels a and b), diabetes duration was the primary splitting factor in women.  In women with 
longer diabetes duration at baseline, no other factors discriminated risk – a discouraging finding 
as diabetes duration is not a modifiable risk factor and the risk in this group is quite high, 
approaching 70% over 25 years of follow-up.  In women with shorter diabetes duration, non-
HDL cholesterol was the only discriminating factor.  Nearly 50% of the shorter duration women 
with non-HDL cholesterol >125 mg/dl developed CVD.  These women ranged in age from 13 to 
30 years old at baseline and thus only 38 to 55 years old at the end of follow-up, so they are at a 
particularly high CVD risk for such a young group. This finding underscores the importance of 
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more aggressive treatment of cholesterol, particularly in younger women, as discussed above. 
Albumin excretion rate only discriminated CVD risk in men.  This supports the earlier 
observation that renal disease may be a more important CVD risk factor in men compared to 
women (56).  Non-HDL cholesterol discriminated risk in men only in the case of lower AER.  In 
men with lower AER, but higher non-HDL cholesterol, waist-hip ratio further discriminated risk, 
supporting the role of insulin resistance in the development of CVD in men.  A measure of 
estimated insulin sensitivity, estimated glucose disposal rate, has been shown to be inversely 
related to cardiovascular outcomes in both sexes in EDC, but men do have lower insulin 
sensitivity, on average, than women (215).  So, as in the case of very high HDL cholesterol in 
women, this observation in men is more likely to be driven by a difference in the distribution of 
waist-hip ratio by sex, rather than by a true sex-specific effect of insulin resistance on CVD risk. 
Finally, when examining the effect of the longitudinal trajectory of HbA1c on CVD risk, 
there was no difference in the trajectory of HbA1c over time by sex.  There was also no evidence 
of a difference in the association between longitudinal HbA1c and CVD by sex, regardless of the 
manifestation of CVD.  This observation is consistent with the recent analyses from the 
DCCT/EDIC, where there was also no difference in the relationship between updated mean 
HbA1c and CVD by sex (187). 
5.2.5 Diabetes Diagnosis Cohort Effects 
One of the greatest strengths of the EDC study is that it represents a wide range of 
diabetes diagnosis years.  This characteristic means that the study cohort lends itself well to 
division into meaningful subcohorts that have experienced different natural histories due to the 
changing nature of diabetes treatment during the follow-up time.  Past analyses stratified by 
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diabetes diagnosis year have helped to quantify the impact of improvements in care, such as the 
initiation of intensive insulin therapy after the results of the DCCT, in an observational setting.  
Specifically, these previous analyses have examined changing incidence of complications over 
the decades of diagnosis years (191), a significant improvement in life expectancy in those 
diagnosed in 1965-1980 compared to 1950-1964 (188), and changing impacts of risk factors 
between those diagnosed in the 1960s versus the 1970s (230).  
In the analyses presented here, separate decision trees were built by diabetes diagnosis 
cohort to explore changes in factors for CVD risk stratification.  In the earlier, 1950-1964 
diagnosis cohort, AER was the only discriminating factor identified, which concurs with the total 
CVD tree, where AER was important at longer diabetes duration.  In contrast, the 1965-1980 
diagnosis cohort first split on non-HDL cholesterol.  In this more recent subcohort, AER only 
discriminated risk at lower levels of non-HDL cholesterol. This difference in the decision trees 
between the two diagnosis subcohorts supports the evidence that there may be a declining role of 
renal disease on CVD.  It has previously been shown that rates of renal disease, particularly end-
stage renal disease, have declined with time (168) and albuminuria has been shown to be less 
likely to precede CVD than reported in earlier studies (194).  
When examining the longitudinal trajectory of HbA1c, we observed differences by 
diagnosis cohort (Figure 10).  The 1950-64 diagnosis cohort had a lower mean baseline HbA1c 
and this difference persisted throughout most of the follow-up.  The HbA1c level in both 
diagnosis cohorts peaked at cycle 6 and then declined thereafter, reflecting the impact of the 
DCCT results being incorporated into clinical practice.  There was, however, a significant 
interaction between diagnosis cohort and time with respect to HbA1c, driven by the steeper 
decline in HbA1c observed after cycle 6 in the 1950-64 cohort, compared to the more recent 
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1965-80 cohort.  Despite this interaction with respect to HbA1c trajectory over time, there was 
no difference in the relationship between longitudinal HbA1c and CVD incidence by diagnosis 
cohort.  
5.3 STRENGTHS AND LIMITATIONS 
The work presented here has many strengths.  The Pittsburgh EDC is a well-characterized 
cohort with over 25 years of prospective follow-up to ascertain mortality and complication 
status, as well as several clinical visits providing repeated measures of clinical characteristics 
over time.  The study includes a wide range of diabetes diagnosis years, which enables analyses 
of the changing natural history of type 1 diabetes.   Deaths and cardiovascular outcomes were 
verified using death certificates, interviews with next of kin, autopsy reports, and medical 
records, as appropriate, and were classified by a committee of physicians who were masked to 
risk factors status.  The novel statistical methods applied to the data addressed key limitations of 
traditional analyses by formally assessing the presence of subgroups and higher-order 
interactions using tree-structured survival analysis and more complete utilization of the available 
repeated measures data on HbA1c using joint models. 
The major limitation of these data is the potential for “healthy survivor” bias due to 
deaths and the exclusion of participants with cardiovascular disease prior to baseline.  This issue 
could lead to an underestimation of the CVD risk in this cohort, as the highest risk participants 
may have died prior to the beginning of follow-up.  We have attempted to address this possibility 
by performing a sensitivity analysis for the estimated CVD rates and also by performing analyses 
separately between the two diagnosis subcohorts (1950-1964 and 1965-1980), since the bias, if 
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present, would occur almost exclusively in the earlier subcohort.  Another limitation of these 
analyses is the restricted availability of CVD hospitalization data from the background 
Allegheny County population.  This particularly impairs our ability to make estimates of excess 
risk that are as precise as those from other countries, where population-level databases are more 
comprehensive and accessible.  Additionally, these data are from a cohort of almost exclusively 
Caucasian (98%) people from Southwestern Pennsylvania and may not reflect the experience of 
all individuals with type 1 diabetes in the United States.  The EDC study is also a hospital-based 
cohort, which may further restrict the generalizability of these results.  However, it has 
previously been shown that the epidemiologic characteristics (167) and mortality experience 
(188) of the EDC closely reflect those of the population-based Allegheny County type 1 diabetes
registry for individuals who were diagnosed during the same period.  Furthermore, it has also 
been shown that patterns of complication incidence in the EDC are similar to those of the 
conventional treatment arm of the DCCT, in a subgroup with similar baseline characteristics 
(194), lending support to the generalizability of the EDC cohort.         
5.4 DIRECTIONS FOR FUTURE RESEARCH 
The results presented here highlight several key questions that remain regarding CVD in 
type 1 diabetes.  One major question is: what is the contemporary burden of CVD in individuals 
with type 1 diabetes who are aged <30 years?  The EDC cohort does not have optimal numbers 
of individuals in this younger age range after 1996 to estimate contemporary CVD risk in this 
group.  Combining EDC data with data from younger individuals also diagnosed at Children’s 
Hospital of Pittsburgh would help to address this issue in a comparable group.  A combined 
104 
analysis would also allow more exploration into changes in factors for risk stratification, as well 
as examination of the impact of the HbA1c trajectory in a group who had a greater proportion of 
their diabetes natural history in the post-DCCT era.  These analyses could also be used to explore 
at what age elevated CVD risk factors begin to translate into clinical CVD events.   
Within the EDC cohort, additional analyses that better account for the effect of 
medications, such as statin therapy, on CVD risk should be undertaken.  In these current 
analyses, the proportion of young adults <45 years old using statins started out very low (<5% in 
1996), but rose to approximately 20% over follow-up.  Analyses that attempt to incorporate the 
effects of statins on CVD incidence would give us a better estimate of the untreated/baseline 
CVD risk and allow us to quantify how this risk is modified by treatment.  Performing these 
analyses by sex is especially important, given the evidence that women are at a greater excess 
risk for CVD and may be undertreated for CVD risk factors. 
As an exploratory method, the decision tree analysis naturally lends itself to many 
follow-up analyses.  One interesting application of these results would be to look within the 
subgroups identified using clinical risk factors to examine differences in novel markers of risk, 
similar to the analysis by Costacou et al. (116).  In that earlier analysis, candidate genes were 
examined.  The EDC study has recently obtained new genotyping data that would now allow a 
genome wide association study (GWAS) to be performed, opening the possibility of identifying 
new genetic markers for CVD risk.  A key question is: why are some individuals who are 
expected to be at high risk for CVD according to their clinical characteristics protected and, 
conversely, why are some individuals expected to be at low risk for CVD susceptible?  Many 
novel risk factors, including genes and cytokines, could be examined in these groups in an 
attempt to further discriminate risk and better predict which individuals will develop CVD.  
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Decision tree methods could also be used to identify better cut-points for treatment targets and to 
inform planning for clinical trials specific to type 1 diabetes.  Rather than identifying a single 
risk factor target level for the entire type 1 diabetes population, this type of machine learning 
method could be used to identify subgroup-specific target levels based on combinations of risk 
factors.  A key limitation of the decision tree analysis is that because it is an exploratory method, 
it that requires external validation before the results could be widely translated.  Collaborating 
with other studies of type 1 diabetes cohorts and registries to validate the factors and cut-points 
for CVD risk stratification should be a priority.     
Expanding on the joint models presented here is another area of future study.  One 
potential direction is to utilize this method or another related method to extend the understanding 
of the progression of glycemia over the natural history of type 1 diabetes and its relationship to 
the development of macrovascular disease.  One problem with translating the results of 
longitudinal cohort studies like the EDC into clinical practice is the lack of complete information 
available to the healthcare provider.  Data from a longitudinal study can be used to examine 
etiologic pathways that may take many years of follow-up to be revealed.  This is in contrast 
with clinically available information, where often only a current snapshot of risk factor levels is 
accessible.  Potentially, this type of joint modeling could be used to create a “2-step” prediction 
model.  For example, cross-sectional HbA1c and other clinical characteristics are entered to first 
predict the longitudinal trajectory of HbA1c over time and then to subsequently translate this 
predicted trajectory into a patient’s risk of developing CVD.  Additionally, statisticians are 
developing and refining methods to jointly model longitudinal risk factors and multiple time-to-
event outcomes (231).  In these models, the longitudinal trajectory of a risk factor can be used to 
predict a sequence of time-to-event outcomes, such as a CVD event and subsequent death. Type 
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1 diabetes is characterized by many different complications, thus applying this type of modeling 
has great potential to increase understanding of the natural history of complication development 
in this population.  The pathways from renal disease to CVD and CVD to mortality are of 
particular interest.  Finally, the two major approaches described here, TSSA and joint modeling, 
could be combined.   First, TSSA could be used to identify major subgroups and then joint 
modeling could be applied within the groups to determine whether trajectories of other 
continuous risk factors differ with respect to time and their relationship to CVD incidence. 
5.5 PUBLIC HEALTH IMPLICATIONS 
We have demonstrated that young adults with type 1 diabetes remain at a significantly 
increased risk of CVD mortality and morbidity compared to the age- and sex-matched 
background population. The excess risk is especially great in younger women. Likewise, risk 
stratification showed that women with shorter diabetes duration at baseline who also have 
elevated non-HDL cholesterol had an approximate 50% risk of developing CVD by age 55.  We 
have also shown that young adults with type 1 diabetes who are between 30-39 years old have a 
6.3% 10-year risk of developing CVD overall, which approaches the 7.5% 10-year risk threshold 
for intensive statin therapy recommended for adults >40 years old by the ACC/AHA (73).   
However, the 10-year risk we estimate for 30-39 years old includes individuals who are already 
on statin therapy, which rose to 20% of the group by the end of follow-up.  Thus, we can 
reasonably assume that the 10-year risk would exceed 7.5% if none of the cohort were using 
lipid-lowering medication.  These results support recommending statin therapy to all individuals 
with type 1 diabetes duration of >20 years who are at least 30 years old.  These findings also 
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underscore the need for cholesterol and blood pressure intervention trials specific to type 1 
diabetes to address the excess risk that remains in this population, particularly in young adults 
and women.          
The relationship between glycemic control and CVD has historically been inconsistent 
across trial data and observational studies.  Here, by utilizing an analysis method that 
incorporates the longitudinal trajectory of glycemia, we have been able to quantify the relative 
CVD risk associated with each unit increase in HbA1c, averaged over the entire longitudinal 
trajectory.  These findings add important information to the understanding of how the 
relationship between hyperglycemia and CVD develops over time.  It supports the need for good 
glycemic control, in addition to lipid and blood pressure control, to prevent CVD in type 1 
diabetes.  
From an analytic standpoint, this work demonstrates the need to consider the limitations 
of traditional statistical methods for analyzing data from longitudinal cohort studies.  The 
relationships between risk factors and disease are complicated and may not be adequately 
represented by traditional methods with assume characteristics such as linearity or do not 
account for changes over time.  The accessibility of computationally intensive methods is ever 
increasing due to higher processing capabilities and the availability of open source programs.   
This body of work has therefore demonstrated a comprehensive examination of the 
epidemiology of CVD and its risk factors in type 1 diabetes. We have quantified the 
contemporary incidence and excess risk of CVD in young adults <45 years old with type 1 
diabetes and have utilized novel statistical methods to address limitations in the analyses of 
longitudinal cohort studies.  These novel methods have enabled us to identify subgroups at 
varying levels of CVD risk and to estimate the association of longitudinal HbA1c with CVD 
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incidence.  This work demonstrates that novel methods should be considered as part of the 
epidemiologic “toolbox” as a complement to more traditional methods to increase understanding 
of disease etiology. 
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APPENDIX A. EXAMINATION OF THE DOSE RESPONSE RELATIONSHIPS 
BETWEEN RISK FACTORS AND CARDIOVASCULAR DISEASE IN TYPE 1 
DIABETES USING RESTRICTED CUBIC SPLINES 
Blood Pressure and 25-Year Risk of Coronary Artery Disease (CAD) by Sex in Type 
1 Diabetes (T1D):  The Pittsburgh Epidemiology of Diabetes Complications (EDC) Study 
Diastolic Blood Pressure (DBP) has been shown to have a J-shaped relationship with 
CAD in many studies.  Trial data have suggested that aggressively lowering BP can have 
detrimental CAD effects, but there is a lack of evidence in T1D.  Thus we aim to model the dose-
response relationship between Systolic BP (SBP) and DBP with CAD incidence separately by 
sex to examine whether there is increased risk at low BP levels and if this relationship differs in 
men and women with T1D. 
Participants in the Pittsburgh EDC, a prospective cohort study of childhood onset T1D, 
were followed for 25 yrs to ascertain CAD incidence (first instance of fatal CAD, myocardial 
infarction, revascularization, coronary stenosis >=50%, ischemic ECG, or angina). Restricted 
cubic splines in Cox models were used to model baseline (1986-88) SBP and DBP on risk of 
110 
CAD in those who were free of prevalent CAD at baseline (n=304 men, 301 women, mean 
age=27, T1D duration=19yrs). 
Over 25 yrs, 109 (35.9%) men and 101 (33.6%) women developed CAD.  SBP had a 
linear association with CAD in both sexes (p<.0001). For DBP, no association was observed in 
men (p=0.21), but a J-shaped association was observed in women (nonlinear p=0.005), with a 
nadir at approximately 75 mmHg (Figure 10).  This nonlinear association remained after 
covariate adjustment (p=0.03).   
These data suggest that the shape of the relationship between diastolic blood pressure and 
CAD differs by sex in T1D.  More research is needed to determine whether aggressive lowering 
of blood pressure is associated with increased risk of CAD in women with T1D.  
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Figure 10.  Hazard Rations Over the Range of Diastolic Blood Pressures (DBP) and 
Coronary Artery Disease by Sex, Restricted Cubic Spline Analysis 
Albumin Excretion Rate (AER) Has A Nonlinear Association With Coronary Artery Disease 
(CAD) Mortality In Type 1 Diabetes (T1D): The Pittsburgh Epidemiology Of Diabetes 
Complications (EDC) Study   
 
 
 
Background:  There is evidence that risk for CAD may increase at AER levels below the 
microalbuminuria threshold (20 μg/min). Accurately determining the shape of this relationship is 
critical for prevention efforts.  We thus modeled the dose-response relationship between AER 
and CAD. 
 
 
H
az
ar
d 
R
at
io
 
DBP(mmHg) DBP(mmHg) 
Men Women 
112 
Methods:  EDC study participants diagnosed with T1D from 1965-1980 and without 
CAD (n=413 mean) were followed for 25 years from baseline (1986-88) when mean T1D 
duration and age were 15 and 23yrs; 50% male. The association between baseline ln(AER) and 
CAD incidence (fatal CAD, MI, revascularization procedure/blockage ≥50%, ischemic ECG or 
angina) and mortality was modeled using Cox proportional hazards with restricted cubic splines 
(five knots at fixed percentiles - 5th: 3.7µg/min, 25th: 7.2µg/min, 50th: 13.9µg/min, 75th:100.5 
µg/min, and 95th:1863 µg/min). 
Results:  There were 95 (23%) cases of incident CAD.  Risk of total CAD increased 
linearly with increasing AER (p<.0001) but adding nonHDL-cholesterol to the model attenuated 
the relationship (p=0.19); there was no evidence for a nonlinear relationship (Figure 11, 
nonlinear effect p=0.55).  Risk of fatal CAD (29 cases) increased between ~12-150 µg/min and 
then remained constant at higher AERs (Figure, adjusted nonlinear effect p=0.01). 
Conclusions: Risk of fatal CAD seems to increase before the 20 µg/min 
microalbuminuria threshold is reached and remains constant at AER>150 µg/min. 
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Figure 11. Log Hazard Ratios Over the Range of ln(Albumin Excretion Rate) and Total 
and Fatal Coronary Artery Disease, Restricted Cubic Spline Analysis 
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APPENDIX B. COMPARISONS OF RELATIVE AND ABSOLUTE RISKS OF 
MORTALITY AND CARDIOVASUCLAR DIEASE ACROSS COUNTRIES 
Table 10. Comparison of EDC Estimated Excess Mortality and CVD with Recent 
International Reports 
EDC Scottish Registry 
Linkage Study (51) 
Swedish National 
Diabetes Register (52) 
Australia (182) 
Follow-Up 
Period 
1996-2012 2005-2007 1998-2011 1997-2003; 
2004-2010* 
Age 
Group 
SMR 
(95% CI) 
Age 
Group 
SMR 
(95% CI) 
Age 
Group 
HR 
(95% CI) 
Age 
Group 
SMR 
(95% CI) 
Total Mortality 
Men 30-39 2.4 
(0.97, 5.0) 
30-39 3.4 
(2.8, 4.0) 
18-34 2.8 
(2.3, 3.5) 
30-39 4.1 (3.6, 4.6);
4.1 (3.6, 4.7)* 
40-44 4.7 
(2.7, 7.6) 
40-49 4.0 
(3.8, 4.2) 
35-49 4.3 
(3.8, 4.8) 
40-49 4.7 (4.3, 5.1);
4.4 (4.0, 4.8)* 
Women 30-39 9.2 
(4.8, 15.9) 
30-39 5.2 
(3.7, 7.2) 
18-34 4.1 
(3.1, 5.4) 
30-39 4.6 (3.9, 5.3);
5.0 (4.2, 5.9) 
40-44 6.7 
(3.4, 11.9) 
40-49 4.7 
(3.6, 6.2) 
35-49 4.4 
(3.7, 5.2) 
40-49 4.7 (4.2, 5.3);
4.2 (3.8, 4.7)* 
Cardiovascular 
Mortality 
Men 30-39 18.5 
(5.9, 44.7) 
- - 18-34 3.5 
(1.9, 6.4) 
- - 
40-44 16.4 
(8.0, 30.0) 
- - 35-49 5.4 
(4.3, 6.8) 
- - 
Women 30-39 63.4 
(25.7, 
131.8) 
- - 18-34 6.9 
(2.8, 17.3) 
- - 
40-44 31.6 
(12.8, 
65.7) 
- - 35-49 7.5 
(5.2, 10.9) 
- - 
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Table 11. Comparison of EDC Estimated Excess CVD with the Scottish Registry Linkage 
Study 
EDC Scottish Registry 
Linkage Study 
Follow-Up Period 1996-2012 2005-2007 
Total CVD 
Incidence 
Age 
Group 
Rate Ratio 
(95% CI) 
Age 
Group 
Rate Ratio 
(95% CI) 
Men 30-39 6.7 
(1.1, 22.0) 
20-39 4.8 
(3.7, 6.2) 
40-44 4.0 
(1.5, 8.9) 
40-49 3.1 
(2.7, 3.6) 
Women 30-39 10.0 
(1.7, 33.0) 
20-39 5.5 
(4.2, 7.2) 
40-44 15.8 
(7.7, 29.0) 
40-49 5.1 
(3.8, 6.8) 
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Table 12. Comparison of EDC Absolute and CVD Mortality with Recent International 
Reports 
EDC Scottish 
Registry 
Linkage Study 
Swedish  
National  
Diabetes Register 
Australia 
Follow-Up 
Period 
1996-2012 2005-2007 1998-2011 2006 
Age 
Group 
Rate per 
100,000 
(95% CI) 
Age 
Group 
Rate per 
100,000 
(95% CI) 
Age 
Group 
Rate per 
100,000 
(95% CI) 
Age 
Group 
Rate per 
100,000 
Total 
Mortality 
Men 30-39 444 
(180, 920) 
30-39 627 
(474, 816) 
≥18 997 
(959, 1035) 
0-39 269 
40-44 1430 
(800, 2287) 
40-49 1236 
(1023, 1481) 
40-60 1198 
Women 30-39 813 
(428, 1409) 
30-39 418 
(281, 599) 
0-39 190 
40-44 1096 
(558, 1946) 
40-49 843 
(642, 1088) 
40-60 689 
CVD 
 Mortality 
Men 30-39 296 
(94, 712) 
- - ≥18 342 
(320, 365) 
0-39 49 
40-44 902 
(441, 1648) 
- - 40-60 338 
Women 30-39 443 
(180, 920) 
- - 0-39 22 
40-44 658 
(267, 1363) 
- - 40-60 128 
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Table 13.  Comparisons of Absolute CVD Incidence with the Scottish Registry Linkage 
Study 
EDC Scottish Registry Linkage 
Study 
Follow-Up Period 1996-2012 2005-2007 
Total CVD 
Incidence 
Age 
Group 
Rate per 
100,000 
(95% CI) 
Age 
Group 
Rate per 
100,000 
(95% CI) 
Men 30-39 1036 
(591, 1690) 
20-39 273 
(197, 369) 
40-44 2705 
(1827, 3858) 
40-49 1154 
(944, 1397) 
Women 30-39 887 
(481, 1503) 
20-39 176 
(110, 276) 
40-44 1974 
(1211, 3041) 
40-49 814 
(613, 1060) 
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